1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000 COMMISSION FILE NUMBER: 000-21429
ARQULE, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 04-3221586
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
OF INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
19 PRESIDENTIAL WAY, WOBURN, MASSACHUSETTS 01801
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES INCLUDING ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
(781) 994-0300
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
(TITLE OF EACH CLASS) NAME OF EACH EXCHANGE ON WHICH REGISTERED
--------------------- -----------------------------------------
None None
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
COMMON STOCK, $.01 PAR VALUE
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of voting stock held by non-affiliates of the
registrant as of March 9, 2001 was: $333,515,737.
There were 20,197,924 shares of the registrant's Common Stock outstanding
as of March 9, 2001.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
2
PART I
ITEM 1. BUSINESS
ArQule seeks to bridge the gap between genomics and clinical development by
applying its proprietary technology platform and chemistry capabilities to drug
discovery. Recent advances in genomics and the completion of the mapping of the
human genome are bringing about a revolution in scientists' understanding of the
molecular mechanisms of disease. Genomics has created explosive growth in the
number of new biological targets for the development of drugs. Fulfilling the
promise of genomics, however, will require similar advances in the technology
and systems used to design and test new chemical compounds which interact with
these targets. Since these chemical compounds will become the medicines of the
future, advances in chemistry technologies hold the key to unlocking the value
of genomics.
Major pharmaceutical companies need to bring three to five new drugs to
market each year to sustain expected growth and profitability. Historically,
researchers have needed to evaluate at least 10,000 compounds for each drug that
ultimately reaches the market. Even if drug candidates make it through discovery
research into the first phase of human trials, up to ninety percent of these
candidates fail to gain final approval. At this level of attrition, large
pharmaceutical companies will need to add 30 to 50 drug candidates per company
per year to their clinical development portfolios. Currently, the discovery
research required to identify a drug candidate takes an average of six years to
complete. Our goal is to shorten this period approximately by half. It then
takes an average of eight more years for the drug candidate to move through
clinical development to the marketplace. The average investment required to
bring a drug to the market, including the cost of failed candidates, is
estimated to be in the range of $350 to $500 million. Consequently, the cost of
failure is high.
The continued success of the pharmaceutical industry will depend on its
ability to significantly reduce the time and cost required to bring a drug to
market, to increase the number of candidates entering clinical development, and
to improve the success rate of clinical testing. ArQule has built an integrated
technology platform incorporating our proprietary AMAP Chemistry Operating
System, patented processes and chemistry capabilities to address these critical
needs of drug discovery. In addition, ArQule will continue to integrate other
technologies into its technology platform. We recently merged with Camitro
Corporation to accelerate the integration of computational models of drug-like
compound characteristics into our technology platform.
THE DRUG DISCOVERY AND DEVELOPMENT PROCESS
[FLOW CHART]
1
3
The drug discovery and development process includes three major components:
Target Identification: The Role of Genomics
Until recently, pharmaceutical researchers were limited to studying
how approximately 400 biological targets interact with chemical compounds.
Targets are proteins or other large molecules that play a fundamental role
in the onset or progression of a particular disease. The number of
available biological targets is being vastly expanded through genomics.
Genomics is the science of identifying genes and their role in biological
processes, including disease and other medical conditions. Scientists now
use genomics to identify genes and the proteins they encode, including
proteins that may become drug discovery targets. Advances in genomics are
accelerating the process of target identification, thereby creating the
potential for a wealth of new targets for drug discovery.
Compound Discovery: From Target to Drug Candidate
The many potential targets identified through genomics are only the
beginning of the process of discovering a potential drug. Through a process
called target selection, scientists seek to confirm that a given target
plays an important role in a disease process. Having identified an
appropriate target, researchers identify chemical compounds that interact
with the target in a process known as lead generation. Lead qualification
is the process of selecting from a group of lead compounds those which have
sufficient drug-like characteristics to justify further evaluation. In a
process known as lead optimization, researchers seek to maximize the
likelihood of a given lead compound becoming a drug by minimizing or
eliminating those characteristics that might interfere with the desired
effect. Researchers must consider a number of factors in optimizing a lead
compound to become a clinical candidate, including effectiveness against
the target and specificity for that target, as well as the following
factors which are referred to by the acronym "ADMET":
- Absorption: whether the compound will be absorbed properly in the
body;
- Distribution: once absorbed, how the compound will be distributed
throughout the body;
- Metabolism: how the compound will change within the body;
- Elimination: whether the compound will be removed from the body in a
harmless way; and
- Toxicity: whether the compound might be toxic to the body and cause
harmful side effects.
Traditionally, researchers have optimized compounds for these various
factors in a largely serial process. For example, researchers have
optimized first for potency, followed by selectivity, and then for various
ADMET properties. Industry analysts estimate that pharmaceutical companies
spend annually between $2 and $4 billion on compound discovery.
Drug Development: From Drug Candidate to Medicine
Following the discovery process, optimized lead compounds must undergo
pre-clinical and clinical development and regulatory approval. This lengthy
and expensive process can take up to ten years, with up to a 90% failure
rate. Unfortunately, a high proportion of the failures occur in the latter,
most expensive phases of the drug development process. For each approved
drug, the total cost of discovery and development, including the cost of
failed clinical candidates, is estimated to be between $350 and $500
million. These high risks are justified by the ultimate potential
reward -- a share of the worldwide market for approved drugs, which in 1998
was approximately $300 billion.
THE COMPOUND DISCOVERY CHALLENGE
We believe that significant advances are being made in the productivity of
the genomics and clinical development phases of drug discovery and development.
However, for these advances to fulfill their potential to improve the efficiency
of the overall drug discovery and development process, similar advances are
required in the compound discovery phase. ArQule believes that the traditional
compound discovery process is
2
4
extremely inefficient and therefore represents a significant opportunity for
value creation. ArQule seeks to use its integrated technology platform to
overcome the following problems:
- DIFFICULTIES IN SELECTING TARGETS. The proliferation of targets will
trigger a need to select those targets that a researcher should pursue
further. The traditional approach to target selection encompasses a
variety of molecular biology techniques which can be time consuming and
labor intensive.
- POOR QUALITY OF INITIAL LEAD COMPOUNDS. Early in the discovery process,
researchers typically lack information about the potential for a lead
compound to become a drug candidate. Consequently, they cannot
efficiently determine or predict which compounds have a greater chance of
success or what changes can be made in the structure of a particular
compound to improve its chances for success. The problems caused by this
lack of information are intensified by the lack of diversity of the
compounds screened. As a result, researchers typically select a single
chemotype for further evaluation and optimization. A chemotype is a core
chemical structure around which families of chemical compounds with
similar structures can be created. If a particular chemotype proves
difficult to optimize and no other chemotype is available, researchers
may waste time and money pursuing related compounds with the same
chemotype, which will share the same problems. Early availability of
alternative chemotypes could increase the likelihood of success against a
particular target.
- INEFFICIENT LEAD OPTIMIZATION PROCESS. Because researchers conduct lead
optimization in sequential steps, rather than in parallel, the
traditional compound discovery process is long and expensive. In the
conventional lead optimization process, medicinal chemists analyze a lead
compound's structure and use their experience to suggest changes that
might produce the desired result for potency or an ADMET characteristic.
Because changes to a compound's structure that enhance one desired
feature of a compound may impair other desired features, the traditional,
sequential lead optimization process is very inefficient, time-consuming
and unpredictable.
The shortcomings in the current compound discovery process create two major
problems for pharmaceutical researchers. First, due in part to the lack of early
information about lead compounds and the lack of alternative chemotypes, very
few lead compounds meet the minimum criteria to become clinical candidates.
Second, of the lead compounds that meet the minimum criteria, too many are only
marginally acceptable clinical candidates and are therefore more likely to fail
during clinical development. Without improvements in this process, the current
failure rate of drug candidates will continue and there will not be enough new
drugs to fuel continued revenue and profit growth of the major pharmaceutical
companies.
THE ARQULE INTEGRATED SOLUTION
ArQule has built an integrated technology platform incorporating our
proprietary AMAP Chemistry Operating System, patented processes and chemistry
capabilities to bridge the gap between targets and clinical candidates. In
addition, our recent merger with Camitro Corporation will enable us to integrate
computational ADMET models as part of our technology platform. Our technology
provides the following benefits:
Our AMAP Chemistry Operating System allows us to perform high-throughput,
automated production of new chemical compounds.
The compound discovery process requires efficient production of a wide
range of chemical compounds. Lead generation requires a large number of
screening compounds; lead optimization requires the rapid creation of
structurally similar compounds, or analogs. The growth in available targets
emerging from genomics will only increase these needs. Our AMAP Chemistry
Operating System allows us to address these issues. The AMAP system forms the
foundation of our parallel synthesis approach to combinatorial chemistry and
consists of an integrated series of automated workstations that perform tasks
such as weighing and dissolution, chemical synthesis, thermally-controlled
agitation and reaction process development. The AMAP system also incorporates
purification, quality control, the ability to re-format libraries and the
ability to replicate libraries for multiple customers. Our proprietary Array
Information Management and Process Control Management System (AIMS/PCMS)
software controls and monitors the overall production process
3
5
within the system. The AIMS/PCMS software allows us to capture information about
every compound in the library, as well as to process this information and to
audit test data.
Our AMAP Chemistry Operating System is highly modular, which makes it easy
to expand production capacity and to add new capabilities. In addition, because
the AMAP Chemistry Operating System incorporates proprietary processes,
software, and equipment, and relies on highly trained operators, we believe that
duplication of the system by others would be difficult or impossible. We hold
U.S. and foreign patents, and have several pending patent applications, covering
various aspects of the AMAP Chemistry Operating System.
We deliver discrete compounds of known structure, high purity and in sufficient
quantity for lead optimization.
Our proprietary AMAP Chemistry Operating System and parallel synthesis
capabilities enable us to produce:
- Discrete Compounds with Known Structures. Parallel synthesis allows us
to produce hundreds of thousands of individual compounds of known
structure every year. Consequently, we can immediately link target
screening data to specific chemical structures, accelerating subsequent
steps in the discovery process.
- Compounds with High Levels of Purity. In 1999, the compounds in each of
our screening libraries were at least 85% pure, on average, with many
libraries exceeding 90% purity. The compounds in our lead optimization
libraries routinely exceed 90% purity, and in many cases exceed 95%
purity. This high level of purity minimizes the incidence of inaccurate
test results in the screening and optimization processes.
- Sufficient Quantities of Each Compound Using Reproducible Methods. We
produce milligram quantities of each compound, which are large quantities
in comparison to the output of other combinatorial compound production
methods. This amount allows researchers to conduct extensive screening
and follow-up work without synthesizing additional quantities. Moreover,
in the event that additional amounts of a compound are required, we can
easily reproduce our compounds in relatively large, highly pure amounts
needed for the later stages of drug discovery.
We can quickly understand how large and small variations in the chemical
structure of a compound will alter its profile as a lead compound.
Our AMAP Chemistry Operating System has allowed us to create compound
libraries based on more than one hundred distinct chemotypes. We continue to add
more than 60 chemotypes to our compound libraries each year. The AMAP system
also allows us to produce thousands of analogs for each chemotype. Screening
these logically designed libraries results in data showing the relationship of
large and small changes in compound structure to activity. With this
structure-activity relationship data, we can rapidly design successive
generations of compounds to accelerate the identification of a lead compound
with improved performance.
We design and produce compound libraries with pre-selected characteristics for
increased likelihood of generating marketable drugs.
Our scientists select chemotypes based on our understanding of drug-like
characteristics and, in some cases, our knowledge of the targets. We then use
proprietary software to evaluate and select building blocks to add to the core
structures with the goal of creating compounds with the desired properties and
diversity. We will enhance our abilities in this area with the integration of
computational ADMET models from Camitro.
Currently, certain chemical structures with drug-like characteristics
cannot be produced in high-throughput processes. Over the past several years, we
have enhanced our AMAP system to enable us to expand the range of chemical
structures with drug-like characteristics that we can produce in high-throughput
processes.
4
6
We reduce screening costs by utilizing smaller, more focused libraries of
compounds.
To streamline the screening process, we have developed a method of
accessing the complete chemical diversity of our compound collection using a
proportionally representative subset called a Compass Array library. The Compass
Array library contains a subset of representative compounds from our full
Mapping Array libraries in the same proportions as they exist in the full
libraries. The results of screening the Compass Array library will direct
subsequent screening to those portions of the full library that are more likely
to contain active compounds for that target. This enables our customers, by
screening the approximately 50,000 compounds in our Compass Array library, to
rapidly identify the most promising chemotypes for further evaluation without
screening our full repository of over half a million compounds.
In addition, to the extent that structural information about a target is
known, our AMAP system permits the creation of specialized, focused arrays of
compounds biased toward that target. These libraries have the capability to
streamline the lead generation and qualification process by allowing
collaborators to focus on compounds most likely to be effective against the
target.
We can perform cost-efficient profiling of compounds for desirable drug
characteristics.
We are supplementing our AMAP system with profiling screens to assess ADMET
characteristics in parallel with compound creation during the lead optimization
process. By enhancing the throughput and automation of these screens, we will
improve the cost-efficiency of generating ADMET data. In addition, we will use
the computational ADMET models from Camitro to screen compounds "in silico" to
predict their ADMET properties before they are synthesized. These computational
and experimental ADMET predictions will allow us to have early access to ADMET
characteristics of compounds. Early access to this data will allow us to
optimize compounds for multiple ADMET properties in parallel, which will
expedite the optimization process and help reduce late stage failures. Moreover,
the relatively small size of our Compass Array library makes it feasible for us
to obtain and store ADMET profiling data on all of the compounds in the library.
This ADMET profiling data will lead to informed decisions as to which initial
screening hits should be pursued for further optimization.
We can use our diverse chemistries to assist in target selection.
We have created compound libraries consisting of small molecules which
interact with a significant number of disease targets. In circumstances where
researchers have identified interesting targets of unknown function, we can
provide libraries which will allow researchers to clarify the role of these
targets in disease. Using chemistry in this way also allows rapid initiation of
the lead optimization process based on the compounds which have been identified.
ARQULE'S STRATEGY
Using our proven technology platform and drug design expertise, we seek to
become the premier independent partner for lead generation, qualification and
optimization programs. We believe we can reduce the time and cost of the
compound discovery process and improve the quality of the compounds that advance
to the clinic. Our strategy includes the following:
- CONTINUE TO INVEST IN CORE TECHNOLOGIES. We will continue to design
improved compounds and to create libraries that streamline the process of
generating, qualifying and optimizing lead compounds. We believe we can
streamline these processes by (a) reducing the number of compounds that
need to be screened without sacrificing diversity, (b) providing early
structure-activity and ADMET data, and (c) performing optimization in
parallel rather than in the traditional serial process. We plan to
continue to build our drug discovery capabilities by developing our own
technologies and by in-licensing or acquiring complimentary technologies,
as with our recent merger with Camitro Corporation.
- BALANCE THE RISKS AND REWARDS OF DRUG DISCOVERY. We seek to balance risk
and reward over time by pursuing three types of collaborations with
different risk/reward profiles.
5
7
- Pharmaceutical Collaborations. We will continue to pursue
collaborations with pharmaceutical companies to provide near-term
revenues in the form of up-front payments and annual license fees. In
comparison to typical biotechnology collaborations, these
collaborations offer lower long term royalties and milestones but
higher current cash flow.
- Biotechnology Collaborations. Our biotechnology collaborations offer
longer-term revenue potential, with a higher risk/reward profile. We
will seek to establish dedicated and focused partnerships with
companies that have a relatively large number of validated targets or
a strong proprietary position in a specific therapeutic area. In these
collaborations, we will seek to advance a compound through the
discovery process in conjunction with our partner on an equal cost-
sharing basis. We will then enter into commercialization agreements
with pharmaceutical company partners at an appropriate point in the
development process, sharing equally in future milestone and royalty
revenues with our biotechnology partner.
- Pursue In-House Drug Discovery. As the final part of our balanced
strategy, we plan to identify and in-license targets and to take these
compounds through the optimization process at our own risk and
expense. We would then out-license these optimized compounds as
clinical candidates to other companies in exchange for cash payments
plus potential milestone and royalty payments. We believe that
licensing drug candidates to outside companies at later stages of the
discovery process would make it possible to capture higher downstream
royalty rates for good clinical candidates.
ARQULE'S TECHNOLOGY
We offer solutions to the shortcomings of the compound discovery process
through our chemistry capabilities which integrate our scientific personnel,
proprietary computer informatics software, and customized robotic workstations.
Our AMAP Chemistry Operating System, which forms the foundation of our
technology, is a highly automated and integrated series of chemistry
workstations and processes designed to enable rapid, parallel generation of
thousands of novel, pure, diverse and spatially-addressed arrays of compounds.
The AMAP system represents the integration of proprietary and patented
technologies in seven areas that results in a consistent, well-defined,
well-monitored, reproducible and flexible process consisting of the following
steps:
- library design
- process chemistry
- production
- purification
- quality control
- culling and reformatting
- replication
LIBRARY DESIGN. To design a library, we first select a chemotype that will
be represented within the library; the chemotype may be target-based or selected
to increase the diversity of the library. We select chemotypes based on input
from our scientists and scientific advisory board as well as information from
our collaborators, literature searches, and biological data. At this stage in
library design, we also identify the potential chemical components or building
blocks needed to create compounds in the library.
Our Library Design department uses our proprietary ArQule Reactor and
MapMaker software to evaluate and then select those building blocks which will
create compounds with the desired properties and diversity. The software then
creates a virtual library of compounds resulting from the reaction of the chosen
building blocks. Our designers calculate the properties of these compounds and
assess their diversity. A resulting list of recommended building blocks serves
as the starting point for the Process Chemistry department.
6
8
PROCESS CHEMISTRY. Before synthesizing an array of actual compounds, the
recommended building blocks must be qualified, and reaction conditions developed
by our Process Chemistry department. Using the list of recommended building
blocks from Library Design, our Process Chemistry department:
- assesses the solubility and reactivity of all building blocks;
- obtains full characterization of the resulting compounds;
- identifies optimal reaction conditions; and
- transitions the production process from bench-scale to an automated
process.
Our Process Chemistry department uses a series of automated workstations to
evaluate the solubility and reactivity of the building blocks. The automation
capabilities of our Process Chemistry department include the following
components:
- Small-Scale Weighing and Dissolution. Weighs and dissolves building
blocks and prepares racks of building block solutions for use in chemical
synthesis.
- Small-Scale Chemical Synthesis. Enables distribution of building blocks
to pre-defined reactors for multi-step chemical reactions.
- Reaction Workup. Removes catalysts, salts, bases, or other extraneous
elements of building blocks. Includes liquid-liquid extraction and
separation methods.
- Quality Control. Analyzes reaction products to confirm chemical
structure, yield and purity.
Once the building blocks and reaction conditions are optimized, the resulting
list of building blocks and synthetic protocols serves as the basis for
synthesis of the full library by the Production department.
PRODUCTION. Our Production department synthesizes libraries of compounds
using a series of automated workstations similar to those used in process
chemistry. Each workstation in the production process, however, has a higher
throughput capacity to support synthesis of a greater number of compounds.
The overall production process is controlled and monitored by our
proprietary AIMS/PCMS software. With this software, we can track the production
process throughout synthesis, characterization, analysis, and final registration
into our library collection. In addition to controlling various aspects of the
AMAP system, the AIMS/PCMS software also collects and stores data in two
databases, one for storing information about compounds and a second for storing
process information and workstation audit data.
Following production, arrays are transferred to either our Quality Control
or Purification department. Some libraries need to be purified before Quality
Control, while other arrays move directly to Quality Control.
PURIFICATION. Our Purification department uses two separation methods to
purify compounds and confirm their structure. Using our proprietary PrepQule
method, all fractions from a high performance liquid chromotography, or HPLC,
run are collected and subjected to flow-injection mass spectrometry analysis for
identification of the fraction(s) containing the desired compound. Using the
commercially available FractionLynx(TM) method, only those HPLC fractions
containing the expected molecular weight are collected and analyzed by mass
spectrometry.
Following identification of fractions containing desired product from
either method, samples are concentrated, quantified, reconstituted, and sent to
the Quality Control department for final analysis.
QUALITY CONTROL. Our Quality Control department develops the analytical
methods used to evaluate compound arrays and evaluates libraries as they arrive
from our Production and Purification departments. Once a library has arrived in
Quality Control, a sequence list is generated using the AIMS/PCMS software. This
list indicates which analytical method will be used to analyze the library and
interfaces with customized software that controls the liquid handling systems
enabling automated analyses. AIMS/PCMS software enables us to view quality
control data for individual compounds, plates, or entire libraries. The
AIMS/PCMS software also produces a customized report based on quality control
data. Data can be automatically compiled
7
9
for all the plates in an array, a specific production run, a specific plate, or
for the original plates of building blocks.
CULLING AND REFORMATTING. Based on analytical results and purity selection
criteria, we may remove some compounds from an array. The AIMS/PCMS software
displays the analytical results for each compound in an array using color-coding
based on user defined thresholds to rapidly and efficiently select individual
compounds that should not be included in the array. Once we select individual
compounds to be culled, the plates are automatically reformatted. This
eliminates the spaces in the array formerly containing the undesired compounds.
REPLICATION. Following final quality control assessment, arrays that will
become part of our Mapping Array repository are sent to our Replication
department. Portions of each compound are removed from the master plates and
used to create sets of plates that are shipped to our collaborators. We then
replicate and store additional sets of plates in our cold room storage facility.
CAMITRO'S TECHNOLOGY
Camitro has developed various computational models for ADMET
characterization of compounds based on their structure. These models will enable
ArQule to profile "virtual libraries" of compounds to decide which compounds to
make from among the thousands or millions of compounds that we could make. The
Camitro models are also useful for compound redesign during lead optimization.
For example, the metabolism models developed by Camitro are unique in their
ability to direct a chemist to change particular sites on a compound to improve
its metabolic stability.
ARQULE'S PRODUCTS
ArQule offers a range of products and services tailored to our customers'
needs for drug discovery assistance. Our products and programs provide solutions
for the lead generation, lead qualification and lead optimization components of
the compound discovery process. We focus on making the compound discovery
process more efficient, less expensive and more likely to result in better
clinical candidates. We believe that, while no single technology platform will
bridge the gap in the drug discovery process between genomics and the clinic,
the integration of multiple emerging technologies will result in major
efficiency gains. For example, our recent merger with Camitro adds the emerging
technology of computational ADMET prediction to our integrated technology
platform, which will improve our ability to identify the right compounds to make
from among the thousands or millions that we could make. In the past, we focused
primarily on production and licensing of compound libraries. We intend to offer
our range of products and services both to customers who need assistance with a
specific aspect of the discovery process and to customers desiring a complete
compound discovery solution. We believe that our integrated technologies will
enable our collaborators to identify and optimize drug candidates in a faster,
less-expensive and more reliable way. Our products include:
Mapping Array Program
We offer our Mapping Array libraries to our collaborators to screen against
their biological targets in order to identify lead compounds. Collaboration
partners can also use our Mapping Array libraries in conjunction with our
Compass Array library or our Target Biased Array libraries to screen compounds
in a more efficient and cost-effective way. We grant subscribers a non-exclusive
license for screening. We grant subscribers an exclusive license on active
compounds identified. We also use our Mapping Array libraries for our own
discovery programs.
Our Mapping Array program provides:
- LARGE NUMBERS OF HIGHLY PURE COMPOUNDS IN SPATIALLY ADDRESSABLE
ARRAYS. Using a combination of technologies including the AMAP Chemistry
Operating System, we produce significant numbers of highly pure, small,
drug-like compounds in spatially addressable arrays of 96-well plates
with a single compound in each well.
8
10
- HIGHLY ORGANIZED ARRAYS ALLOW RAPID SCREENING AND OPTIMIZATION. We
design Mapping Array compounds with systematic variation of diverse
building blocks on multiple scaffolds. As a result, each compound in the
array differs from adjacent compounds by a single structural
modification. This allows structure-activity relationship data to be
generated from primary screening data. This patented, proprietary process
allows researchers to rapidly navigate through a logically organized
series of modifications to the core chemical structure of the compound
and to rapidly optimize active molecules.
- INCREASED CHEMICAL DIVERSITY EACH YEAR. Each year, we add approximately
200,000 new compounds to our Mapping Array repository, including 60 or
more new chemotypes.
Compass Array Program
We offer our Compass Array program to our collaborators as a focused and
streamlined approach to lead generation and qualification. We designed the
Compass Array library to identify rapidly those arrays contained within our
Mapping Array repository that warrant further evaluation without the need to
screen the entire compound library. Our Compass Array library contains
approximately 50,000 compounds representing a 12.5% subset of the entire
chemical diversity contained in our Mapping Array repository.
Compass Array Screening Advantage
[FLOW CHART]
Researchers can use screening results from the Compass Array library to
identify arrays from the Mapping Array repository that are of interest. We then
supply our collaborator with the arrays that they identify, which average 3,000
compounds per array. Further screening of these full arrays identifies
additional potent, selective compounds of interest. This process ensures that
the related compounds within any active chemotype have been tested and that the
structure-activity relationship patterns within the corresponding Mapping Array
libraries have been thoroughly explored.
Directed Array Program for Lead Optimization
We offer Directed Array libraries for use in lead optimization. We create
Directed Array libraries as focused collections containing between 1,000 and
2,500 analogs of the lead compound. The collaborator receives each compound in a
single well format, and we arrange the library in accordance with our patented,
spatially-addressable array format to facilitate collection and analysis of
structure-activity relationship data. We also send information files with each
library that define the structures and molecular weights for all of the
compounds along with their exact location (plate, column, row) within the array.
In the past, we have used the Directed Array program to take a lead
compound provided by our collaborator through a parallel process of systematic
structural modifications to enhance and maximize the potency of the compound. In
the future, we intend to offer a Directed Array program as part of an integrated
process for general lead optimization, which would seek to optimize a lead
compound for selectivity and ADMET criteria in addition to potency. Under this
proposed program, we envision taking a collaborator's lead
9
11
compound through a parallel process of systematic structural modifications and
testing to select and optimize many of the desired compound features, including
potency, selectivity and ADMET criteria. By using lead compounds derived from
our libraries, we anticipate that we will have greater flexibility in pursuing
lead optimization because:
- we will have more usable information about the structure of the compound;
- we will have easier access to analogs from our own libraries; and
- we will have greater knowledge of possible back-up compounds and
alternative structures generated from "hits" detected in our libraries
during the screening and lead generation and qualification process.
Target-Biased Array
We also intend to develop and offer specialized, focused arrays of
compounds biased toward particular targets. Under this program, we envision
collaborators providing us with information about their own proprietary targets
so that we can then use our expertise in combinatorial chemistry and library
building to assemble focused libraries of compounds most likely to have an
affinity for that target. These libraries would streamline the lead generation
and qualification process by allowing collaborators to focus on compounds most
likely to be effective against that target.
Custom Array Program
Our Custom Array program generates custom compound libraries based on
specifications provided by a collaborator. This results in compounds which are
exclusively available to an individual collaborator.
AMAP Technology Transfer
We offer our customers an option of licensing our AMAP Chemistry Operating
System on a non-exclusive basis, allowing them to produce their own
combinatorial libraries.
Two sizes of the AMAP Chemistry Operating System are available: a
large-scale AMAP Chemistry Operating System capable of producing more than
200,000 compounds per year; and a small-scale AMAP Chemistry Operating System
capable of producing between 50,000 and 100,000 compounds per year. Transfers of
both the large-scale and small-scale systems include equipment, training and
installation.
Predictive ADMET Models
Through our wholly owned subsidiary -- Camitro Corporation -- we intend to
offer our customers access to a suite of predictive models for ADMET
characterization of compounds. This suite will be initially focused on modeling
for human intestinal absorption, blood brain barrier penetration and metabolism
by the 3A4 isoenzyme of cytochrome P450. Additional components will be added to
this integrated suite over time.
Integrated Drug Discovery Platform
By combining our AMAP(TM) technology for high throughput, automated
chemistry; our intelligent design of compounds for optimal potency, selectivity
and ADMET characteristics; and a parallel process for drug discovery we intend
to offer an integrated drug discovery platform for potential collaboration with
large pharmaceutical partners.
10
12
OUR COLLABORATIONS
Pharmaceutical Collaborations
The following table summarizes our collaborations with pharmaceutical
companies:
COMPANY PRODUCTS/SERVICES PROVIDED
- ------- --------------------------
Pfizer Inc. .................. Technology transfer of AMAP Chemistry Operating System and
Custom Array libraries
Bayer AG...................... Custom Array libraries
American Home Products, Wyeth-
Ayerst Division............. Mapping Array and Directed Array libraries
Solvay Duphar B.V. ........... Mapping Array, Compass Array and Directed Array libraries
and a non-exclusive license to our AMAP Chemistry Operating
System
G.D. Searle, a division of
Pharmacia Corp. ............ Mapping Array, Directed Array and Compass Array libraries
and lead optimization services
Sankyo Company, Ltd. ......... Mapping Array and Directed Array libraries
Johnson & Johnson, Inc. ...... Mapping Array libraries and Compass Array libraries
GlaxoSmithKline............... Compass Array libraries and lead optimization services
Abbott Laboratories(1)........ Mapping Array and Directed Array libraries
Roche Bioscience(1)........... Directed Array libraries
- ---------------
(1) The collaboration portion of these agreements ended in March 1999, but the
collaboration partner is still obligated to make payments upon the
achievement of specified milestones and to pay royalties on sales of drugs
that may result from the collaboration.
Pfizer. In July 1999, we entered into a four and one half year technology
acquisition agreement with Pfizer Inc. We will manage and staff a dedicated
facility containing an AMAP Chemistry Operating System for Pfizer in Medford,
Massachusetts. The facility will produce Custom Array libraries exclusively for
Pfizer. Pfizer will own all rights in compounds produced at this facility. In
addition, we will train Pfizer staff to use our AMAP Chemistry Operating System.
At the end of the collaboration, Pfizer will receive a non-exclusive license to
the AMAP Chemistry Operating System. We expect to receive up to $117 million
dollars over the term of the agreement. We have received a $15.8 million upfront
payment and will potentially receive up to $27 million per calendar year for
compound production, technology access, and operating costs. As of December 31,
2000, we have received $40.4 million under this agreement. Pfizer may terminate
the agreement after two and one half years for any reason, with payment of a
termination fee and return of the AMAP Chemistry Operating System. Pfizer will
pay no milestones or royalties to us on compounds which they develop and market.
Bayer. In October 1999, we entered into a three-year collaboration with
Bayer AG to produce Custom Array libraries. Bayer will own all rights in
compounds for an initial period, after which we will co-own rights in compounds
that Bayer has not claimed in a patent application. We received a $3 million
upfront payment and will receive up to an additional $27 million during the term
of the agreement in delivery and success fees. As of December 31, 2000, we have
received $5.0 million under this agreement. Bayer will pay no milestones or
royalties to us on compounds which they develop and market.
American Home Products, Wyeth-Ayerst Division. In July 1997, we entered
into a five-year agreement with Wyeth-Ayerst Pharmaceuticals, a division of
American Home Products Corporation. Under this agreement, Wyeth-Ayerst
subscribed to our Mapping Array program and has committed to a minimum number of
Directed Array Programs. Wyeth-Ayerst made a $2 million equity investment in
ArQule in June 1998, and is committed to make payments totaling $26.2 million
during the course of the agreement. As of December 31, 2000, we have received
$22.0 million under this agreement and we have not received any milestone or
royalty payments. In addition, Wyeth-Ayerst has agreed to pay us development
milestones and royalties from the sales of products resulting from the
collaboration.
11
13
Solvay. In November 1995, we entered into a five-year agreement with
Solvay Duphar B.V. Under this agreement, Solvay subscribed to our Mapping Array
and Directed Array programs and received a non-exclusive license to our AMAP
Chemistry Operating System. This agreement was superseded by an amended and
restated agreement with Solvay Pharmaceuticals B.V., which became effective on
January 1, 2001. The amended agreement extends the collaboration through
December 31, 2003. Under the amended agreement, Solvay receives our Compass
Array libraries and continues to access our Mapping Array libraries and Directed
Array programs. We received a total of $18.1 million under the original
agreement. Solvay is committed to make additional payments totalling $2.5
million under the amended agreement. Solvay has also agreed to make additional
payments if we achieve certain development milestones and to pay royalties on
sales of any drugs that result from the relationship. To date, we have not
received any milestone or royalty payments. In connection with this
collaboration, an affiliate of Solvay, Physica B.V., made a $7 million equity
investment in ArQule.
Pharmacia. We entered into a five-year collaboration with Monsanto Company
(now Pharmacia Corporation) in December 1996. Under this agreement, we provided
Monsanto with access to our Mapping and Directed Array programs for use in the
development of agrochemicals. In January 2000, we expanded this collaboration to
cover life science applications, including pharmaceutical use by Monsanto's G.D.
Searle division, and extended the term until 2002. We also agreed to provide
Monsanto with Compass Array and Mapping Array libraries through 2001 and Compass
Array libraries only through 2002. We also converted the Monsanto agrochemical
Directed Array Program into a credit for pharmaceutical lead optimization
services. Pharmacia is committed to make payments totaling $12.7 million under
this agreement. In addition, Monsanto has agreed to pay us development
milestones and royalties from the sales of products resulting from the
collaboration. In July 1998, we received a milestone payment for a Mapping Array
compound selected by Monsanto for entry into field trials. On June 30, 2000, in
connection with the merger between Monsanto and Pharmacia, we replaced our
existing collaboration agreement with a new collaboration agreement with G.D.
Searle & Co., a division of Pharmacia. The financial terms of the new agreement
are substantially the same as the prior agreement. However, we expanded the
scope of the agreement to enable Pharmacia and its affiliates to screen our
compounds, which may result in milestone and royalty payments in the future. To
date, we have received $12.3 million under this agreement.
Sankyo. In November 1997, we entered into a three-year agreement with
Sankyo Company, Ltd. to discover and optimize drug candidates. Under the terms
of the agreement, Sankyo received a subscription to our Mapping Array program to
discover new lead compounds. Sankyo has also committed to a minimum number of
Directed Array Programs during the term of the agreement. The total value of the
agreement is up to $9 million in committed payments. To date, we have received
$7.8 million under this agreement. Sankyo has also agreed to pay us
developmental milestones and royalties resulting from sales of any products
resulting from this collaboration. To date, we have not received any milestone
or royalty payments under this agreement.
Johnson & Johnson. In December 1998, we entered into a four-year
collaboration with R.W. Johnson Pharmaceutical Research Institute, a division of
Johnson & Johnson, Inc., in which R.W. Johnson subscribed to our Mapping Array
program. During the term of the agreement, R.W. Johnson has committed to pay us
an aggregate of $8.1 million to deliver Mapping Array libraries. As of December
31,2000, we have received $6.0 million under this agreement. In addition, R.W.
Johnson has agreed to pay us developmental milestones and royalties from sales
of any products resulting from this collaboration. We have not received any
milestone or royalty payments. On August 14, 2000, we amended our collaboration
agreement with R.W. Johnson to discover new lead compounds for a variety of
therapeutic areas. The amended agreement includes a subscription to our Compass
Array libraries in lieu of other deliverables. The amendment did not alter the
financial terms of the agreement.
GlaxoSmithKline. In November 2000, we entered into a five-year
collaboration and license agreement with SmithKline Beecham Corporation (now
GlaxoSmithKline). Under the terms of the agreement, GlaxoSmithKline receives
access to our Compass Array libraries and Mapping Array libraries for screening
primarily in the anti-infective field. In addition, GlaxoSmithKline has
committed to submit two drug discovery programs to us during the course of the
agreement. We have initiated the first of the two drug
12
14
discovery programs based on a lead compound discovered in a GlaxoSmithKline
compound library. We will initiate the second drug discovery program when and if
GlaxoSmithKline decides to develop a lead compound discovered in an ArQule
compound library. GlaxoSmithKline receives all rights in compounds developed in
these drug discovery programs. As of December 31, 2000, we have received no
payments under this collaboration. We will receive more than this minimum amount
if GlaxoSmithKline continues the first drug discovery program beyond the minimum
period and when and if GlaxoSmithKline begins the second drug discovery program.
GlaxoSmithKline may terminate the agreement before the end of the five-year
term. GlaxoSmithKline has agreed to pay us development milestones and royalties
on sales of products resulting from the collaboration. To date, we have not
received any milestone or royalty payments.
Abbott Laboratories. In June 1995, we entered into an agreement with
Abbott Laboratories. Under this agreement Abbott subscribed to our Mapping Array
and Directed Array programs. This collaboration was extended on two occasions
and ended successfully in March 1999. Abbott has agreed to pay us developmental
milestones and royalties from sales of any products resulting from this
collaboration. We have not received any milestone or royalty payments from
Abbott.
Roche Bioscience. In September 1996, we entered into an agreement with
Roche Bioscience. Under this agreement, we synthesized Directed Array compounds.
Our obligations under this agreement ended in March 1999. Roche Bioscience has
agreed to pay us developmental milestones and royalties from sales of any
products resulting from this collaboration. In May 1999, we received a milestone
payment from Roche Bioscience for a Directed Array compound that was chosen for
Investigational New Drug application, or IND, enabling toxicology studies.
Biotechnology Collaborations
In the past, we have entered into a number of collaborations with
biotechnology companies, primarily providing them with access to our Mapping
Array libraries. Going forward, we intend to enter into a select number of
focused biotechnology collaborations with companies who can contribute
significant numbers of important targets, generally around a specific target
class or therapeutic area. These collaborations will pool the necessary
resources from each company to conduct a drug discovery program aimed at
delivering at least one IND candidate per collaboration. We intend to share
equally in the costs and downstream benefits derived from these collaborations.
Genome Therapeutics Corporation. On October 17, 2000, we entered into a
collaborative drug discovery agreement with Genome Therapeutics Corporation to
discover and develop anti-infective drug candidates. Under the agreement, we
will use our Parallel Track Drug Discovery program to screen and optimize
compounds against a significant number of proprietary validated anti-infective
targets which Genome Therapeutics has derived from its PathoGenome(TM) Database.
We will share equally in all downstream value created by the collaboration,
including future milestone, royalty and upfront payments resulting from the
outlicensing of clinical candidates or later stage compounds derived from the
collaboration.
Acadia Pharmaceuticals. On December 18, 2000, ArQule and ACADIA
Pharmaceuticals entered into a drug discovery collaboration. Under the agreement
ACADIA will combine its functional genomics platform with ArQule's Parallel
Track(TM) Drug Discovery program to discover novel small molecule drug
candidates directed at individual G-protein coupled receptor (GPCR) targets. We
will share intellectual property resulting from the collaboration, and equally
contribute to at least one joint drug discovery program. We will share revenues
resulting from the commercialization of joint drug discovery programs. In
addition to these joint drug discovery programs, each of us will receive
exclusive rights to certain compounds that we have decided not to develop in a
joint drug discovery program, subject to a royalty payment to the other party.
On April 7, 1998, we entered into a material transfer and screening agreement
with ACADIA. Under this agreement, we provided to ACADIA access to certain
ArQule compound arrays for screening against their target collection. On May 10,
2000, we entered into a compound license agreement with ACADIA. Under this
agreement, we granted to Acadia an exclusive license to certain of our compounds
having activity against certain of their targets, in return for payments and
royalties.
13
15
PATENTS AND PROPRIETARY RIGHTS
We have a number of issued U.S. and foreign patents, and numerous patent
applications in the U.S. and other countries. We depend, in part, on these
patents to protect our technology and products. We also rely upon our trade
secrets, know-how and continuing technological advances to develop and maintain
our competitive position. In an effort to maintain the confidentiality and
ownership of our trade secrets and proprietary information, we require our
employees and consultants to sign confidentiality and invention assignment
agreements. We intend these agreements to protect our proprietary information by
controlling the disclosure and use of technology to which we have rights. These
agreements also provide that we will own all the proprietary technology
developed at ArQule or developed using our resources.
COMPETITION
The biotechnology industry is highly competitive. Our services and products
face competition based on several factors, including size, diversity and ease of
use of compound libraries. We also face competition related to the speed and
costs of identifying and optimizing potential lead compounds and our patent
position. We compete with many organizations that are engaged in attempting to
identify and optimize compounds. For chemistry services, our competitors include
Discovery Partners International, Array Biopharma, Medichem, Albany Molecular
Research Institute and Biofocus. We compete with Vertex Phamaceuticals,
Neurogen, and 3-Dimensional Pharmaceuticals for chemistry-based drug discovery.
In addition, we also compete with academic and scientific institutions,
governmental agencies and public and private research organizations.
Smaller companies may also prove to be significant competitors,
particularly through arrangements with large corporate collaborators. In
addition to competition for our customers, these organizations also compete with
us in recruiting and retaining highly qualified scientific and management
personnel.
Historically, pharmaceutical companies have maintained close control over
their research activities, including the synthesis, screening and optimization
of chemical compounds. Many of these companies, which represent a significant
potential market for our products and services, are developing in-house
combinatorial chemistry and other methodologies to improve productivity,
including major investments in robotics technology to permit the automated
parallel synthesis of compounds. In addition, these companies may already have
large collections of compounds previously synthesized or ordered from chemical
supply catalogs or other sources against which they may screen new targets.
Other sources of compounds include extracts from natural products such as plants
and microorganisms and compounds created using rational design. Academic
institutions, governmental agencies and other research organizations are also
conducting research in areas in which we are working either on their own or
through collaborative efforts.
GOVERNMENT REGULATION
Our research and development processes involve the controlled use of
hazardous materials. Although we are subject to federal, state and local laws
and regulations governing the use, manufacture, storage, handling and disposal
of these materials and waste products, the license or sale of our products is
not subject to significant government regulations. Our future profitability,
however, depends on our collaborators selling pharmaceuticals and other products
developed from our compounds that may be subject to government regulation.
Virtually all pharmaceutical and biotechnology products developed by our
collaborative partners will require regulatory approval by governmental agencies
prior to commercialization. The nature and the extent to which these regulations
apply to our collaborative partners varies depending on the nature of their
products. In particular, human pharmaceutical products and biologics are subject
to rigorous preclinical and clinical testing and other approval procedures by
the FDA and by foreign regulatory authorities. Various federal and, in some
cases, state statutes and regulations also govern or influence the
manufacturing, safety, labeling, storage, record keeping and marketing of these
products. The process of obtaining these approvals and the subsequent compliance
with appropriate federal and foreign statutes and regulations are time consuming
and require substantial resources.
14
16
Generally, in order to gain FDA approval, a company first must conduct
preclinical studies in the laboratory and in animal models to gain preliminary
information on a compound's efficacy and to identify any safety problems. The
results of these studies are submitted as a part of an IND that the FDA must
review before human clinical trials of an investigational drug can start. In
order to commercialize any products, we or our collaborator will be required to
sponsor and file an IND and will be responsible for initiating and overseeing
the clinical studies to demonstrate the safety and efficacy that are necessary
to obtain FDA approval. Clinical trials are normally done in three phases and
generally take several years, but may take longer to complete. After completion
of clinical trials of a new product, FDA and foreign regulatory authority
marketing approval must be obtained. If the product is classified as a new
pharmaceutical, we or our collaborator will be required to file a New Drug
Application, or NDA, and receive approval before commercial marketing of the
drug. Similarly, if the product is a new biologic, a biological license
application, BLA, must be filed and must receive approval prior to commercial
marketing of the product. The testing and approval processes require substantial
time and effort. NDAs and BLAs submitted to the FDA can take several years to
obtain approval.
Even if FDA regulatory clearances are obtained, a marketed product is
subject to continual review. If and when the FDA approves any of our
collaborators' products under development, the manufacture and marketing of
these products will be subject to continuing regulation, including compliance
with current Good Manufacturing Practices, known as GMPs, adverse event
reporting requirements and prohibitions on promoting a product for unapproved
uses. Later discovery of previously unknown problems or failure to comply with
the applicable regulatory requirements may result in restrictions on the
marketing of a product or withdrawal of the product from the market as well as
possible civil or criminal sanctions.
For marketing outside the United States, we will be subject to foreign
regulatory requirements governing human clinical trials and marketing approval
for pharmaceutical products and biologics. The requirements governing the
conduct of clinical trials, product licensing, pricing and reimbursement vary
widely from country to country.
EMPLOYEES
As of March 9, 2001, we employed 304 people, of whom 107 have Ph.D.
degrees. 127 of our employees were engaged in operations, 141 were engaged in
research and development, and 36 were engaged in marketing and general
administration. None of our employees are covered by collective bargaining
agreements. We believe that we have good relations with our employees.
OUR TRADEMARKS
The terms "ArQule", "Mapping Array", and "Directed Array" are trademarks of
ArQule that are registered in the U.S. Patent and Trademark Office. The terms
"Compass Array", "AMAP", "Custom Array", "ArQule Reactor", "MapMaker", "Parallel
Track", and "PrepQule" are trademarks of ArQule.
15
17
ITEM 1A. EXECUTIVE OFFICERS AND DIRECTORS OF THE REGISTRANT
Set forth below is certain information regarding our current executive
officers and directors, including their respective ages, as of March 9, 2001:
NAME AGE POSITION
- ---- --- --------
Dr. Stephen A. Hill................... 42 President, Chief Executive Officer and
a Director
Philippe Bey, Ph.D. .................. 58 Senior Vice President of Research and
Development and Chief Scientific
Officer
David C. Hastings..................... 39 Vice President, Chief Financial
Officer and Treasurer
Harold E. Selick, Ph.D................ 46 President, Chief Executive Officer of
Camitro Corporation
L. Patrick Gage, Ph.D................. 58 Director
Michael Rosenblatt, M.D. ............. 52 Director
Werner Cautreels, Ph.D. .............. 47 Director
Laura Avakian......................... 55 Director
Tuan Ha-Ngoc.......................... 48 Director
Ariel Elia............................ 65 Director
STEPHEN A. HILL, M.D. Stephen A. Hill, B.M., B.Ch., M.A., F.R.C.S. has
served as our President and CEO since April 1999. Prior to his employment with
us, Dr. Hill was the Head of Global Drug Development at F. Hoffmann-La Roche
Ltd. He joined Roche in 1989 as Medical Adviser to Roche Products in the United
Kingdom. He held several senior positions there, including that of Medical
Director, with responsibility for clinical trials of compounds across a broad
range of therapeutic areas, including those of CNS, HIV, cardiovascular,
metabolic, and oncology products. Dr. Hill also served as Head of International
Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland, where he
led the regulatory submissions for seven major new chemical entities globally.
He also was a member of Roche's Portfolio Management, Research, Development and
Pharmaceutical Division Executive Boards. Prior to Roche, Dr. Hill served for
seven years with the National Health Service in the United Kingdom, in General
and Orthopedic Surgery. Dr. Hill is a Fellow of the Royal College of Surgeons of
England, and holds his scientific and medical degrees from St. Catherine's
College at Oxford University.
PHILIPPE BEY, PH.D. Philippe Bey, Ph.D. has served as our Chief Scientific
Officer and Senior Vice President of Research and Development since August 1999.
Dr. Bey has previously held various senior management positions at Hoechst
Marion Roussel (HMR), Marion Merrell Dow, Inc. and Selectide, a combinatorial
chemistry company fully owned by HMR. While at HMR, he coordinated U.S. Research
& Development programs and participated in a task force that defined HMR's
strategic plans. At Marion Merrell Dow, where he served as Vice President of
Global Research, he designed research strategies to incorporate new technologies
and internal organizational competencies while improving productivity. Dr. Bey
also served as President of Selectide. Dr. Bey earned his BS and Ph.D. Chemistry
qualifications at the Louis Pasteur University in Strasbourg, France, and
conducted post-doctoral training at the California Institute of Technology in
Pasadena.
DAVID C. HASTINGS David C. Hastings has served as our Vice President and
Chief Financial Officer since February 2000. Prior to his employment with us,
Mr. Hastings was Vice President and Corporate Controller at Genzyme, Inc. where
he was responsible for the management of the finance department. Prior to his
employment with Genzyme, Mr. Hastings was the Director of Finance at Sepracor,
Inc. where he was primarily responsible for Sepracor's internal and external
reporting. Mr. Hastings is a Certified Public Accountant and received his BA in
Economics at the University of Vermont.
HAROLD E. SELICK, PH.D. Harold E. Selick has served as President and Chief
Executive Officer of Camitro since November 1999. Prior to his employment with
Camitro, Dr. Selick was Vice President of Research of Affymax Research
Institute, where he directed activities in combinatorial chemistry-based drug
discovery, with particular emphasis on the development of technologies for
improving the process of lead optimization. Prior to joining Affymax, Dr. Selick
held scientific positions in two other biotech companies, one of which was
Protein Design Labs, where he was co-inventor of the technology underlying the
creation of fully
16
18
humanized antibodies. He applied this technology to the creation of the "Smart
anti-TAC" antibody, which was successfully developed by Roche as "Zenapax", for
treating kidney transplant rejection. Prior to working at Protein Design Labs,
he was a Damon Runyon-Walter Winchell Cancer Fund Fellow with Professor Bruce
Alberts and an American Cancer Society Fellow at the University of California,
San Francisco, School of Medicine. Dr. Selick holds a Ph.D. in Molecular Biology
and a B.A. in Biophysics from the University of Pennsylvania.
L. PATRICK GAGE, PH.D. L. Patrick Gage, Ph.D. has been a director since
January 1998. Since March 1998, Dr. Gage has been the President of Wyeth-Ayerst
Research, a division of American Home Products Corporation, a pharmaceutical
company. Prior to that, Dr. Gage was employed by Genetics Institute, Inc., a
biopharmaceutical company, in a variety of positions including President.
MICHAEL ROSENBLATT, M.D. Michael Rosenblatt, M.D. has been a director
since April 1998. From 1992-1998, Dr. Rosenblatt served as the Robert H. Ebert
Professor of Molecular Medicine at the Harvard Medical School, Chief of the
Division of Bone and Mineral Metabolism at Beth Israel Hospital, and the
director of the Harvard MIT Division of Health Sciences and Technology. Since
1993, he has also been a faculty member in the department of Biological
Chemistry and Molecular Pharmacological, Biological and Biomedical Sciences
Program of the Division of Medical Sciences at Harvard University. From
1996-1999, he has been the executive director of the Carl J. Shapiro Institute
for Education and Research at Harvard Medical School and Beth Israel Deaconess
Medical Center. Since 1996, he has been Harvard faculty dean for academic
programs at the Beth Israel Deaconess Medical Center. He is now the President
(interim) of Beth Israel Deaconess Medical Center and the George R. Minot
Professor of Medicine at Harvard Medical School. Prior to 1992, Dr. Rosenblatt
was the Senior Vice President for Research at Merck Research Laboratories, a
pharmaceutical company. Dr. Rosenblatt serves as a director of Curis, Inc. and
certain privately held companies.
WERNER CAUTREELS, PH.D. Werner Cautreels, Ph.D. has been a director since
September 1999. Since May 1998, Dr. Cautreels has been the Global Head of
Research and Development of Solvay Pharmaceuticals. Prior to that, Dr. Cautreels
had been employed by Nycomed Amersham Ltd., Sterling Winthrop, and Sanofi in a
variety of positions in Research and Development.
LAURA AVAKIAN Laura Avakian has been a director since March 2000. Ms.
Avakian is currently Vice President for Human Resources for the Massachusetts
Institute of Technology where she directs all human resource programs and
oversees the institution's Medical Department. Prior to joining MIT, she was
Senior Vice President, Human Resources, for Beth Israel Deaconess Medical Center
and for its parent corporation CareGroup. She has previously served as President
of the American Society for Healthcare Human Resources Administration, and has
received the distinguished service award, literature award and chapter
leadership award from that society. She received the 1996 Award for Professional
Excellence in Human Resources Management from the Society for Human Resource
Management. She has also served as editor of the Yearbook of Healthcare
Management and authored numerous chapters and articles on human resources
management. Ms. Avakian received her BA degree from the University of Missouri
at Columbia and her MA degree from Northwestern University.
TUAN HA-NGOC Tuan Ha-Ngoc has been a director since March 2000. Mr.
Ha-Ngoc is the founder, Chief Executive Officer and a director of eHealthDirect,
Inc., which provides an advanced business to business financial transactions
platform for health care benefits administration. Mr. Ha-Ngoc was previously the
Vice President of Strategic Development at American Home Products Corporation
where he directed its corporate strategy in the pharmaceuticals industry. Prior
to joining AHP, he was an Executive Vice President for Genetics Institute, Inc.
Mr. Ha-Ngoc is a member of the Board of Fellows and Chairman of the Research
Committee at the Harvard School of Dental Medicine. He is also a member of the
Board of Trustees of the Lupus Foundation. Mr. Ha-Ngoc received an MBA from
INSEAD and received a Master's Degree in Pharmacy from the University of Paris,
France.
ARIEL ELIA Ariel Elia has been a director since September 2000. Currently,
Mr. Elia serves as Chairman of the European Advisory Board of E.Med Securities,
a private, U.S.-based company providing investment banking services to emerging
growth companies in the life science industry. Mr. Elia is a director of Altamir
S.A., a French venture capital company, and of Yssum, the research and
development company of
17
19
the Hebrew University of Jerusalem in Israel. Mr. Elia also serves as a Governor
of both the Ben Gurion University and the Hebrew University of Jerusalem, in
Israel. Prior to his current positions, Mr. Elia was the Chief Executive Officer
of Jouveinal Laboratories, a privately held, French pharmaceutical company. Mr.
Elia also spent 17 years with Merck & Co., serving both in Europe and in the
U.S., most recently as Senior Vice President, International Division. Before
joining Merck & Co., Mr. Elia spent 12 years with American Home Products Corp.,
serving as President of the International Household Products Division prior to
his departure. Mr. Elia is a U.S. citizen born in Alexandria, Egypt. He
graduated from Victoria College in Alexandria, Egypt with an Oxford and
Cambridge degree as a bachelor of arts. His honors include Knight of the Order
of the Crown in Belgium, and Doctor of Philosophy Honoris Causa of Ben Gurion
University, Israel.
ITEM 2. PROPERTIES
In November 1999, we moved our main operations to a new facility in Woburn,
Massachusetts, which includes approximately 128,000 square feet of laboratory
and office space. This facility was designed to our specific requirements. On
November 28, 2000, we exercised our options to purchase the entire building and
the adjacent lot, and on March 2, 2001 we closed the transaction. The total
consideration paid for the properties was $20.5 million, of which $18.2 million
represented the purchase price for the entire building and the land on which it
sits and $2.3 million represented the purchase price for the adjacent lot. The
purchase price was determined through an arms-length negotiation with Metro
North Corporate Center LLC and Metro North Corporate Center LLC II, which are
unaffiliated with us or any of our directors or executive officers.
We paid $4.5 million in cash and granted a mortgage for the remainder of
the purchase price through an extension of our existing term loan with Fleet
Bank dated as of March 18, 1999, with an initial interest rate of 6.95%. The
land upon which our facility sits is approximately 7.2 acres, including a
parking lot, while the adjacent parcel of land represents approximately 5 acres.
We plan to continue to use our facility in its current capacity and may develop
the adjacent parcel at a presently undetermined time in the future.
Our research facilities also include approximately 56,000 square feet of
laboratory and office space in Medford, Massachusetts, the majority of which is
dedicated to the Pfizer collaboration. We lease these facilities under two lease
agreements, one of which expires on July 30, 2005 and one of which expires on
July 30, 2006. We sublease these facilities pursuant to three sublease
agreements. The monthly cost of these leases is entirely offset by our income
from these subleases.
In connection with our acquisition of Camitro Corporation on January 29,
2001, we assumed Camitro's existing lease for approximately 24,958 square feet
of office space in Menlo Park, California, which will expire on September 30,
2002. Prior to expiration, we have the option to renew this lease for a term of
18 months. We sublease approximately 5,750 square feet of this space under an
agreement which terminates on March 31, 2001. Our lease payments are $45,034 per
month, and our income from the sublease is $11,271 per month. We believe that
all of our facilities are adequate for our current operations.
Subsequent to year-end, Camitro Corporation, through its wholly-owned
subsidiary Camitro UK, Ltd. leased approximately 10,000 square feet of office
and laboratory space in Cambridge, England for 15,416 British Pounds per month.
We lease this facility under an agreement which expires in December 2005. In
March 2001, we executed a two year sublease with a third party for approximately
4,000 square feet of the premises for 7,333 British Pounds per month. This
sublease extends until March 2003.
ITEM 3. LEGAL PROCEEDINGS
None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to stockholders for a vote during the fourth
quarter of 2000.
18
20
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER
MATTERS
ArQule's common stock is traded on The Nasdaq National Market under the
symbol "ARQL".
The following table sets forth, for the periods indicated, the range of the
high and low closing sale prices for ArQule's common stock:
HIGH LOW
----- -----
1999
First Quarter............................................... 7.50 4.38
Second Quarter.............................................. 5.25 3.66
Third Quarter............................................... 7.06 4.25
Fourth Quarter.............................................. 11.13 5.13
2000
First Quarter............................................... 37.50 8.25
Second Quarter.............................................. 19.88 6.25
Third Quarter............................................... 24.13 16.63
Fourth Quarter.............................................. 33.75 13.00
2001
First Quarter (through March 9, 2001)....................... 31.25 15.88
As of March 9, 2001, there were approximately 99 holders of record and
approximately 5,159 beneficial shareholders of our common stock.
We have never paid cash dividends on our common stock and we do not
anticipate paying any cash dividends in the foreseeable future. We currently
intend to retain future earnings, if any, for use in our business.
19
21
ITEM 6. SELECTED FINANCIAL DATA
The following data, insofar as it relates to the years 1996, 1997, 1998,
1999 and 2000, have been derived from ArQule's audited financial statements,
including the balance sheet as of December 31, 1999 and 2000 and the related
statements of operations and of cash flows for the three years ended December
31, 2000 and notes thereto appearing elsewhere in this Annual Report on Form
10-K. This data should be read in conjunction with the Financial Statements and
the Notes thereto and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" appearing elsewhere in this Annual Report
on Form 10-K. The historical results are not necessarily indicative of the
results of operations to be expected in the future. This data is in thousands,
except per share data.
YEAR ENDED DECEMBER 31,
----------------------------------------------------
1996 1997 1998 1999 2000
------- ------- ------- -------- -------
STATEMENT OF OPERATIONS DATA:
Revenue................................. $ 7,255 $17,420 $22,193 $ 18,582 $50,296
Cost and expenses:
Cost of revenue....................... 4,739 10,218 14,036 17,457 21,343
Research and development.............. 3,076 4,704 10,427 14,260 18,579
Marketing, general and
administrative..................... 2,850 4,670 6,387 6,022 8,293
------- ------- ------- -------- -------
Total costs and expenses...... 10,665 19,592 30,850 37,739 48,215
------- ------- ------- -------- -------
Income (loss) from operations........... (3,410) (2,172) (8,657) (19,157) 2,081
Interest income (expense), net.......... 417 2,463 2,195 1,724 1,774
------- ------- ------- -------- -------
Net income (loss)....................... $(2,993) $ 291 $(6,462) $(17,433) $ 3,855
======= ======= ======= ======== =======
Basic net income (loss) per share....... $ (1.32) $ .03 $ (0.54) $ (1.38) $ 0.28
======= ======= ======= ======== =======
Weighted average common shares
outstanding -- basic.................. 2,272 11,282 12,031 12,606 13,911
======= ======= ======= ======== =======
Diluted net income (loss) per share... $ (1.32) $ .02 $ (0.54) $ (1.38) $ 0.25
======= ======= ======= ======== =======
Weighted average common shares
outstanding -- diluted................ 2,272 12,394 12,031 12,606 15,208
======= ======= ======= ======== =======
DECEMBER 31,
----------------------------------------------------
1996 1997 1998 1999 2000
------- ------- ------- ------- --------
BALANCE SHEET DATA:
Cash, cash equivalents and marketable
securities............................ $37,086 $49,282 $33,870 $36,421 $110,019
Working capital......................... 31,440 46,023 35,546 17,371 93,437
Total assets............................ 43,509 66,925 60,480 77,346 149,476
Long-term debt.......................... 1,728 1,213 306 10,700 7,200
Total stockholders' equity.... 34,621 57,340 54,267 38,753 120,420
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
We are engaged in the production and development of novel chemical
compounds with commercial potential in the pharmaceutical and biotechnology
industries. We primarily manufacture arrays of synthesized compounds for
delivery to our customers for use in lead compound generation and lead compound
optimization activities. We also offer other research and development services
to meet the needs of our customers. In addition, we have established a number of
joint drug discovery programs with biotechnology companies and academic
institutions, and are pursuing a limited number of our own internal drug
discovery programs.
20
22
We primarily generate revenue through our collaborative agreements for
production and delivery of compound arrays and other research and development
services. Under most of these collaborative agreements, we are also entitled to
receive milestone and royalty payments if the customer develops products
resulting from the collaboration. To date, we have received two milestone
payments and no royalty payments. In addition, we have not yet realized any
significant revenue from our joint discovery programs with biotechnology
companies and academic institutions, or from our internal drug discovery
programs. While we expect our revenue to increase in 2001, our financial
performance may vary from expectations, including quarterly variations in
performance, because levels of revenue are dependent on expanding or continuing
existing collaborations, entering into additional corporate collaborations,
receiving future milestones and royalty payments, and realizing value from
ongoing drug discovery programs, all of which are difficult to anticipate.
We will continue to invest in technologies that enhance and expand our
capabilities in drug discovery. These continued investments in technology are
intended to enhance the novelty, diversity, and medical relevance of our
compound arrays and to augment the power and scope of our chemistry
capabilities. In addition to investments in technology, we may invest in
internal lead optimization programs with the goal of delivering clinical
candidates. In November 1999, we moved our main operations to a new facility in
Woburn, Massachusetts, which includes 128,000 square feet of laboratory and
office space. Investments of this nature may result in near term earnings
fluctuations or impact the magnitude of profitability or loss.
In November 2000 we sold 3,358,000 shares of common stock at $22.50 per
share in a follow-on public offering. This included the exercise of the
overallotment option of 438,000 shares. The offering resulted in net proceeds of
approximately $70,867,000.
We have incurred a cumulative net loss of $30.7 million through December
31, 2000. Losses have resulted principally from costs incurred in research and
development activities related to our efforts to develop our technologies and
from the associated administrative costs required to support those efforts.
While we were profitable in fiscal year 2000, we will not be profitable in 2001
and our ability to achieve sustained profitability is dependent on a number of
factors, including our ability to perform under our collaborations at the
expected cost, expand or continue existing collaborations, timing of additional
investments in technology and the realization of value from the development and
commercialization of products in which we have an economic interest, all of
which are difficult to anticipate.
The Management's Discussion and Analysis of Financial Condition and Results
of Operation contains forward-looking statements reflecting management's current
expectations regarding our future performance. Such expectations are based on
certain assumptions regarding the progress of product development efforts under
collaborative agreements, the executions of new collaborative agreements and
other factors relating to our growth. Such expectations may not materialize if
product development efforts are delayed or suspended, if negotiations with
potential collaborators are delayed or unsuccessful or if other assumptions
prove incorrect.
RESULTS OF OPERATIONS
Years Ended December 31, 1999 and 2000
Revenue. Total revenues for 2000 were $50.3 million as compared to $18.6
million in 1999, an increase of $31.7 million or approximately 171 percent. This
increase is primarily due to the amortization of upfront fees of approximately
$15.3 million and fees for delivery of Custom Array(TM) sets of approximately
$10.7 million to Pfizer Inc and Bayer AG and from other delivery fees earned
from our collaborations.
Cost of revenue. Cost of revenue in 2000 totaled $21.3 million, an
increase of $3.8 million or 22 percent as compared to 1999. The increase in
costs of revenue was attributable to increased costs for producing Custom
Array(TM) sets for Pfizer Inc and Bayer AG. Our gross margin as a percentage of
sales was 58 percent for the year ended December 31, 2000 as compared to 6
percent for the prior year. Our gross margin as a percentage of sales was higher
in 2000 due to the higher gross margin on the Pfizer collaboration and other
economies of scale.
Research and development expenses. Research and development expenses in
2000 were $18.6 million, an increase of $4.3 million or 30 percent as compared
to $14.3 million in 1999. This increase is the result of
21
23
our ongoing efforts to augment and enhance our chemistry capabilities and
related proprietary technologies, including increased personnel, as we expand
our lead optimization programs.
Marketing, general and administrative expenses. Marketing and general
administrative expenses in 2000 were $8.3 million in 2000, an increase of $2.3
million or 38 percent as compared to 1999. The increase was due primarily
associated with increased administrative costs, including increased personnel,
to support our growth during 2000.
Net investment income. Net investment income consists primarily of
interest income partially offset by interest expense and other non-operating
income and expenses. Investment income in 2000 was $2.9 million as compared to
$1.9 million in 1999, an increase of $1.0 million or approximately 50 percent.
Interest expense in 2000 was $1.1 million as compared to $0.2 million in 1999,
resulting primarily from our higher average debt balance on our term loan with
Fleet National Bank.
Net income (loss). Our net income for the year ended December 31, 2000 was
$3.9 million, compared to a net loss of $(17.4) million for the same period in
1999. Our net income in 2000 has been primarily attributable to increased
revenue from our collaborator base.
Years Ended December 31, 1998 and 1999
Revenue. Revenue for 1999 decreased $3.6 million to $18.6 million from
$22.2 million for the same period in 1998. This decrease reflected the
completion of our collaborative agreements with Roche and Abbott, while not yet
recognizing significant revenues from the collaborative agreements entered into
with Pfizer and Bayer in 1999. We recorded $0.8 million and $3.0 million of
revenue from Roche in 1999 and 1998, respectively. We recorded no revenue from
Abbott in 1999 compared to $1.7 million of revenue in 1998.
Cost of revenue. Cost of revenue for 1999 increased $3.5 million to $17.5
million from $14.0 million for the same period in 1998. This increase is
primarily attributable to the overhead and depreciation related to additional
facilities and scientific personnel and the necessary supplies and overhead
expenses related to the delivery of the Mapping Array and Directed Array sets
pursuant to our collaborative agreements, as well as approximately $0.4 million
of charges related to the relocation of our corporate headquarters in November
1999. These charges primarily related to direct moving expenses as well as
charges incurred to reserve for vacated space in Medford.
Research and development expenses. Research and development expenses for
1999 increased $3.9 million to $14.3 million from $10.4 million for the same
period in 1998. This increase is the result of our ongoing efforts to augment
and enhance our chemistry capabilities and related proprietary technologies.
Marketing, general and administrative expenses. Marketing, general and
administrative expenses for 1999 decreased $0.4 million to $6.0 million from
$6.4 million for the same period in 1998. This decrease is primarily due to a
$0.5 million reduction in the use of outside marketing and consulting services.
Net investment income. Net investment income for 1999 decreased $0.5
million to $1.7 million from $2.2 million for the same period in 1998. Lower
interest income in 1999 resulted primarily from lower amounts available for
investment in 1999.
Net loss. The net loss for 1999 was $17.4 million as compared to a net
loss of $6.5 million for the same period in 1998. The net loss for 1999 is
primarily attributable to decreased revenue, increased expenditures as we
invested in new technologies to expand our drug discovery capabilities, and
charges related to the relocation of our headquarters.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 2000, we held cash, cash equivalents and marketable
securities with a value of $110.0 million, compared to $36.4 million at December
31, 1999. Our working capital at December 31, 2000 was $93.4 million. We have
funded operations through December 31, 2000 with sales of common stock, payments
from corporate collaborators, and the utilization of bank financing. On March
18, 1999, we consummated a term loan agreement with Fleet National Bank to
support our facilities expansion. Under this agreement, we
22
24
borrowed $14.0 million of the potential $15.0 million available. As of December
31, 2000, we have made principal payments of $3.3 million and had an outstanding
balance of $10.7 million.
Cash flows from operating activities for the year ended December 31, 2000
decreased $6.3 million to $6.5 million from $12.8 million for the same period in
1999. This decrease reflects primarily the timing of payments from our corporate
collaborations. Cash flows provided by investing activities for the year ended
December 31, 2000 increased $29.4 million to $1.3 million. We had a use of cash
of $28.1 million from investing activities for the same period in 1999. During
1999 we completed our facility expansion in Woburn, which included approximately
$18.4 million in tenant improvements. Cash flows from financing activities for
the year ended December 31, 2000 increased $60.3 million to $74.1 million from
$13.8 million for the same period in 1999. In November 2000, we completed a
follow-on offering of 3.4 million shares of our common stock that raised $70.7
million net of expenses.
We expect that our available cash and marketable securities, together with
operating revenues and investment income will be sufficient to finance our
working capital and capital requirements for the foreseeable future. Our cash
requirements may vary materially from those now planned depending upon the
results of our drug discovery and development strategies, our ability to enter
into any additional corporate collaborations in the future and the terms of such
collaborations, the results of research and development, the need for currently
unanticipated capital expenditures, competitive and technological advances,
acquisitions and other factors. We cannot guarantee that we will be able to
obtain additional customers for our products and services, or that such products
and services will produce revenues adequate to fund our operating expenses. If
we experience increased losses, we may have to seek additional financing from
public or private sales of our securities, including equity securities. There
can be no assurance that additional funding will be available when needed or on
acceptable terms.
RECENT ACCOUNTING PRONOUNCEMENTS
In June 1998, SFAS No. 133, "Accounting for Derivative Instruments and
Hedging Activities", was issued, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments
embedded in other contracts, and for hedging activities. We are required to
adopt SFAS No. 133, as amended by SFAS No. 137, "Accounting for Derivative
Instruments and Hedging Activities -- Deferral of the Effective Dates of FASB
Statement 133," on a prospective basis for interim periods and fiscal years
beginning January 1, 2001. Had we implemented SFAS No. 133 in the current
period, financial position and results of operations would not have been
affected.
SEC Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements," ("SAB 101") issued in December 1999, summarizes certain of the
Staff's views in applying generally accepted accounting principles to revenue
recognition in financial statements. The statements in the Staff Accounting
Bulletins represent interpretations and practices followed by the Division of
Corporation Finance and the Office of the Chief Accountant in administering the
disclosure requirements of the Federal securities laws. We adopted these SAB 101
during the fourth quarter of 2000 and results of operations were not affected.
SUBSEQUENT EVENTS
In January 2001, we acquired Camitro Corporation, a privately-held
predictive modeling company based in Menlo Park, California. Under the terms of
the merger agreement, we issued approximately 3.4 million shares of our common
stock and $1.7 million in cash in exchange for all of Camitro's outstanding
shares and the assumption of all of Camitro's outstanding stock options and
warrants. The merger transaction was valued at $84.7 million based on our share
price on the measurement date for the merger. The transaction will be accounted
for as a purchase transaction.
In November 2000, we exercised our options to purchase our building and the
adjacent lot in Woburn, Massachusetts and in March 2001 we closed the
transaction. The total consideration paid for the properties was $20.5 million,
of which $18.2 million represented the purchase price for the entire building
and the land on which it sits and $2.3 million represented the purchase price
for the adjacent lot. The purchase price was
23
25
determined through an arms-length negotiation with Metro North Corporate Center
LLC and Metro North Corporate Center LLC II, which are unaffiliated with us or
any of our directors or executive officers.
We paid $4.5 million in cash and granted a mortgage for the remainder of
the purchase price through an extension of our existing term loan with Fleet
Bank dated as of March 18, 1999, with an initial interest rate of 6.95%. The
land upon which our facility sits is approximately 7.2 acres, including a
parking lot, while the adjacent parcel of land represents approximately 5 acres.
We plan to continue to use our facility in its current capacity and may develop
the adjacent parcel at a presently undetermined time in the future.
FACTORS AFFECTING FUTURE OPERATING RESULTS
Our future operating results could differ materially from the results
described above due to the risks and uncertainties described in exhibit 99.1 to
this Annual Report on Form 10-K.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We own financial instruments that are sensitive to market risk as part of
our investment portfolio. Our investment portfolio is used to preserve our
capital until it is used to fund operations, including our research and
development activities. None of these market -- risk sensitive instruments are
held for trading purposes. We invest our cash primarily in money market mutual
funds and U.S. Government and other investment grade debt securities. These
investments are evaluated quarterly to determine the fair value of the
portfolio. Our investment portfolio includes only marketable securities with
active secondary or resale markets to help insure liquidity. We have implemented
policies regarding the amount and credit ratings of investments. Due to the
conservative nature of these policies, we do not believe we have material
exposure due to market risk. Additionally, we entered into an interest rate swap
agreement with Fleet National Bank primarily to reduce the impact of changes in
interest rates on our cash flows. The impact on our financial position and
results of operations from likely changes in interest rates is not material.
See Notes 2 and 7 to the Consolidated Financial Statements for a
description of the Company's use of derivatives and other financial instruments.
The carrying amounts reflected in the consolidated balance sheet of cash and
cash equivalents, trade receivables, and trade payables approximates fair value
at December 31, 2000 due to the short-term maturities of these instruments.
ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
PAGE
----
Report of Independent Accountants........................... 25
Consolidated Balance Sheet at December 31, 1999 and 2000.... 26
Consolidated Statement of Operations for the three years
ended December 31, 2000................................... 27
Consolidated Statement of Stockholders' Equity for the three
years ended December 31, 2000............................. 28
Consolidated Statement of Cash Flows for the three years
ended December 31, 2000................................... 29
Notes to Consolidated Financial Statements.................. 30
Consolidated Financial Statement Schedules:
Schedules are not included because they are not applicable
or the information is included in the Notes to
Consolidated Financial Statements
24
26
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and
Stockholders of ArQule, Inc.
In our opinion, the accompanying consolidated balance sheet and the related
consolidated statements of operations, of stockholders' equity and of cash flows
present fairly, in all material respects, the financial position of ArQule, Inc.
at December 31, 1999 and 2000, and the results of operations and cash flows for
each of the three years in the period ended December 31, 2000, in conformity
with accounting principles generally accepted in the United States of America.
These financial statements are the responsibility of the Company's management;
our responsibility is to express an opinion on these financial statements based
on our audits. We conducted our audits of these statements in accordance with
auditing standards generally accepted in the United States of America which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
/s/ PRICEWATERHOUSECOOPERS LLP
Boston, Massachusetts
January 11, 2001, except as to Footnote 14,
which is as of March 14, 2001
25
27
ARQULE, INC.
CONSOLIDATED BALANCE SHEET
DECEMBER 31,
--------------------------
1999 2000
----------- -----------
(IN THOUSANDS, EXCEPT
SHARE AND PER SHARE DATA)
ASSETS
Current assets:
Cash and cash equivalents................................. $ 4,208 $ 86,079
Marketable securities..................................... 32,213 23,940
Accounts receivable....................................... 2,529 1,564
Accounts receivable -- related party...................... 1,424 718
Inventory................................................. 486 400
Prepaid expenses and other current assets................. 579 1,326
-------- --------
Total current assets.............................. 41,439 114,027
Property and equipment, net................................. 34,093 33,699
Other assets................................................ 1,814 1,750
-------- --------
$ 77,346 $149,476
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of capital lease obligations.............. $ 316 $ --
Current portion of long term debt......................... 2,525 3,500
Accounts payable and accrued expenses..................... 5,719 4,171
Deferred revenue.......................................... 15,508 12,919
-------- --------
Total current liabilities......................... 24,068 20,590
Deferred revenue............................................ 3,825 1,266
Long term debt.............................................. 10,700 7,200
-------- --------
Total liabilities................................. 38,593 29,056
-------- --------
Commitments (Note 11)....................................... -- --
Stockholders' equity:
Preferred stock, $0.01 par value; 1,000,000 shares
authorized; no shares issued or outstanding............ -- --
Common stock, $0.01 par value; 30,000,000 shares
authorized; 12,864,225 and 17,072,727 shares issued and
outstanding at December 31, 1999 and 2000,
respectively........................................... 129 171
Additional paid-in capital................................ 73,167 151,084
Accumulated deficit....................................... (34,538) (30,683)
Unrealized gain on marketable securities.................. -- 29
Deferred compensation..................................... (5) (181)
-------- --------
Total stockholders' equity........................ 38,753 120,420
-------- --------
$ 77,346 $149,476
======== ========
The accompanying notes are an integral part of these consolidated financial
statements.
26
28
ARQULE, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31,
---------------------------------------
1998 1999 2000
---------- ----------- ----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Revenue
Compound development revenue.............................. $11,868 $ 9,421 $40,507
Compound development revenue -- related party............. 10,325 9,161 9,789
------- -------- -------
22,193 18,582 50,296
------- -------- -------
Costs and expenses:
Cost of revenue........................................... 7,506 8,851 13,888
Cost of revenue -- related party.......................... 6,530 8,606 7,455
Research and development.................................. 10,427 14,260 18,579
Marketing, general and administrative..................... 6,387 6,022 8,293
------- -------- -------
30,850 37,739 48,215
------- -------- -------
Income (loss) from operations.......................... (8,657) (19,157) 2,081
Investment income........................................... 2,364 1,915 2,865
Interest expense............................................ (169) (191) (1,091)
------- -------- -------
Net income (loss)...................................... $(6,462) $(17,433) $ 3,855
======= ======== =======
Basic net income (loss) per share........................... $ (0.54) $ (1.38) $ 0.28
======= ======== =======
Weighted average common shares outstanding -- basic......... 12,031 12,606 13,911
======= ======== =======
Diluted net income (loss) per share......................... $ (0.54) $ (1.38) $ 0.25
======= ======== =======
Weighted average common shares outstanding -- diluted....... 12,031 12,606 15,208
======= ======== =======
The accompanying notes are an integral part of these consolidated financial
statements.
27
29
ARQULE, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
UNREALIZED
COMMON STOCK ADDITIONAL GAIN TOTAL
---------------------- PAID-IN ACCUMULATED DEFERRED MARKETABLE STOCKHOLDERS'
SHARES PAR VALUE CAPITAL DEFICIT COMPENSATION SECURITIES EQUITY
---------- --------- ---------- ----------- ------------ ---------- -------------
(IN THOUSANDS, EXCEPT SHARE DATA)
Balance at December 31, 1997..... 11,878,090 $119 $ 68,418 $(10,643) $ (554) $ 57,340
Stock option exercises........... 134,639 1 793 794
Employee stock purchase plan..... 53,619 1 381 382
Issuance of common stock in
connection with American Home
Products investment in ArQule,
Inc............................ 104,987 1 1,999 2,000
Compensation related to the grant
of common stock options........ (159) 159 --
Amortization of deferred
compensation................... 213 213
Net loss......................... (6,462) (6,462)
---------- ---- -------- -------- ------- --- --------
Balance at December 31, 1998..... 12,171,335 122 71,432 (17,105) (182) 0 54,267
Stock option exercises........... 536,473 5 888 893
Employee stock purchase plan..... 156,417 2 538 540
Compensation related to the grant
of common stock options........ 309 (309) --
Amortization of deferred
compensation................... 486 486
Net loss......................... (17,433) (17,433)
---------- ---- -------- -------- ------- --- --------
Balance at December 31, 1999..... 12,864,225 129 73,167 (34,538) (5) 0 38,753
Stock option exercises........... 758,403 8 5,670 5,678
Employee stock purchase plan..... 92,099 1 533 534
Issuance of common stock in
connection with secondary
public offering, net of
insurance costs of $4,864...... 3,358,000 33 70,658 70,691
Compensation related to the grant
of common stock options........ 1,056 (1,056) --
Amortization of deferred
compensation................... 880 880
Unrealized gain on marketable
securities..................... 29 29
Net income....................... 3,855 3,855
---------- ---- -------- -------- ------- --- --------
Balance at December 31, 2000..... 17,072,727 $171 $151,084 $(30,683) $ (181) $29 $120,420
========== ==== ======== ======== ======= === ========
The accompanying notes are an integral part of these consolidated financial
statements.
28
30
ARQULE, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
YEAR ENDED DECEMBER 31,
--------------------------------
1998 1999 2000
-------- -------- --------
(IN THOUSANDS)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
Cash flows from operating activities:
Net income (loss)........................................ $ (6,462) $(17,433) $ 3,855
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization......................... 4,620 7,690 7,350
Amortization of deferred compensation................. 213 486 880
(Increase) decrease in accounts receivable............ (2,575) 1,755 1,671
Decrease in inventory................................. 427 40 86
(Increase) decrease in prepaid expenses and other
current assets...................................... (349) 290 (747)
(Increase) decrease in other assets................... (1,500) (158) 64
Decrease in notes receivable from related parties..... 197 30 --
Increase (decrease) in accounts payable and accrued
expenses............................................ (710) 3,625 (1,548)
Increase (decrease) in deferred revenue............... (1,488) 16,427 (5,148)
-------- -------- --------
Net cash provided by (used in) operating
activities....................................... (7,627) 12,752 6,463
-------- -------- --------
Cash flows from investing activities:
Purchases of marketable securities....................... (44,109) (57,731) (58,302)
Proceeds from sale or maturity of marketable
securities............................................ 50,164 53,608 66,604
Proceeds from tenant improvement allowance............... -- -- 2,335
Additions to property and equipment...................... (9,787) (23,962) (9,291)
-------- -------- --------
Net cash (used in) provided by investing
activities....................................... (3,732) (28,085) 1,346
-------- -------- --------
Cash flows from financing activities:
Principal payments of capital lease obligations.......... (1,174) (897) (316)
Borrowings of long term debt............................. -- 14,000 --
Principal payments of long term debt..................... -- (775) (2,525)
Proceeds from issuance of common stock, net.............. 3,176 1,433 76,903
-------- -------- --------
Net cash provided by financing activities........... 2,002 13,761 74,062
-------- -------- --------
Net increase (decrease) in cash and cash equivalents....... (9,357) (1,572) 81,871
Cash and cash equivalents, beginning of period............. 15,137 5,780 4,208
-------- -------- --------
Cash and cash equivalents, end of period................... $ 5,780 $ 4,208 $ 86,079
======== ======== ========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
During 1998, 1999, and 2000 the Company paid approximately $169, $191 and
$1,091, respectively, for interest expense.
The accompanying notes are an integral part of these consolidated financial
statements.
29
31
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
1. ORGANIZATION AND NATURE OF OPERATIONS
ArQule, Inc. is engaged in the discovery, development and production of
novel chemical compounds primarily for the pharmaceutical and biotechnology
industries. Our operations are focused on the integration of combinatorial
chemistry, structure-guided rational drug design, computational models of
drug-like compound characteristics and other proprietary technologies which
automate the process of chemical synthesis to produce arrays of novel small
organic chemical compounds used to generate and optimize drug development and
product development candidates.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant accounting policies followed in the preparation of these
financial statements are as follows:
Basis of Consolidation
The consolidated financial statements include the accounts of ArQule, Inc.
and its majority-owned subsidiary ArQule Catalytics, Inc., which was
incorporated in February 1998 (collectively, "we", "us", "our" and the
"Company"). All intercompany transactions and balances have been eliminated.
Cash Equivalents and Marketable Securities
We consider all highly liquid investments purchased within three months of
maturity date to be cash equivalents. We invest our available cash primarily in
money market mutual funds and U.S. government and other investment grade debt
securities that have strong credit ratings. As a matter of policy, ArQule
determines on a quarterly basis the fair market value of its investment
portfolio. Unrealized gains and losses on securities are included in the income
of shareholders equity, net of related tax effects. If the fair market value of
a marketable security declines below its cost basis, and, based upon our
consideration of all available evidence, we conclude such decline is "other than
temporary", we mark the investment to market through a charge to current
earnings. At December 31, 1999 and 2000, we have classified these investments as
available-for-sale.
Fair Value of Financial Instruments
At December 31, 1999 and 2000, our financial instruments consist of cash,
cash equivalents, marketable securities, accounts receivable, notes receivable
from a related party, accounts payable, accrued expenses and our interest rate
swap. The carrying amounts of these instruments approximate their fair values.
Property and Equipment
Property and equipment are recorded at cost and depreciated using the
straight-line method over their estimated useful lives. Assets under capital
leases and leasehold improvements are amortized over the shorter of their
estimated useful lives or the term of the respective leases by use of the
straight-line method. Maintenance and repair costs are expensed as incurred.
Revenue Recognition
Compound development revenue relates to revenue from significant
collaborative agreements and from licensing of compound arrays. Revenue from
collaborative agreements includes the delivery of compounds and compound
development work recognized using the percentage of completion method. The
application of this revenue recognition method is dependent on the terms of the
contractual arrangement. Accordingly, revenue is recognized on the proportional
achievement of deliveries against a compound delivery schedule or as development
labor is expended against a total research and development labor plan. Revenue
from compound
30
32
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
delivery also includes technology transfer fees and fees based on the delivery
of compounds. Since the technology transfer fees are included in agreements that
also include compound delivery, the technology transfer fees are recognized
ratably over the performance period. Fees related to the delivery of compounds
are based upon the delivery of compounds. Milestone payments are recognized as
revenue based upon the stage of completion of our performance obligations under
the related contract. Accordingly, upon achievement of a milestone, an amount
equal to the milestone payment multiplied by the percentage of our performance
obligation completed through that date is recognized as revenue. The remainder
will be recognized ratably over the remaining term of the performance period.
Payments received under these arrangements prior to the completion of the
related work are recorded as deferred revenue. We believe our revenue
recognition policies are in full compliance with Staff Accounting Bulletin 101,
"Revenue Recognition in Financial Statements" ("SAB 101"). We did not change any
of our revenue recognition policies as a result of implementing SAB 101.
Cost of Revenue
Cost of revenue represents the actual costs incurred in connection with
performance pursuant to collaborative agreements and the costs incurred to
develop and produce compound arrays. These costs consist primarily of payroll
and payroll-related costs, chemicals, supplies and overhead expenses.
Research and Development Costs
Research and development costs are expensed as incurred. These costs
consist primarily of payroll and payroll-related costs, chemicals, software,
supplies, and overhead expenses.
Stock Compensation
Options granted to employees and members of the Board of Directors are
accounted for in accordance with Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" (APB No. 25) and related
interpretations. Under APB No. 25, no compensation expense is recognized for
options granted at fair market value with fixed terms. We have adopted the
disclosure requirements of Statement of Financial Accounting Standards No. 123,
"Accounting for Stock Based Compensation" (SFAS No. 123). All stock-based awards
granted to nonemployees, including members of the Scientific Advisory Board, are
accounted for as prescribed by SFAS No. 123 and Emerging Issues Task Force
96-18, "Accounting for Equity Instruments that are Issued to Other than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services." We
believe our stock compensation policies are in compliance with FASB
Interpretation No. 44, "Accounting for Certain Transactions Involving Stock
Compensation."
Inventories
Inventory, consisting only of raw materials, comprises costs associated
with our Mapping Array libraries and is stated at the lower of cost, on a
first-in, first-out basis, or market. Such costs are capitalized after achieving
technological feasibility.
Segment Data
We are principally engaged in one industry segment. We also operate
principally in one geographic location, the United States. See Note 12 with
respect to significant customers.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and
31
33
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from these estimates.
Reclassifications
Certain reclassifications have been made to the 1998 and 1999 financial
statements to conform to the 2000 presentation.
Earnings (Loss) Per Share
We compute and report earnings per share in accordance with the provisions
of SFAS No. 128, "Earnings Per Share". The computations of basic and diluted
earnings (loss) per common share are based upon the weighted average number of
common shares outstanding and potentially dilutive securities. Potentially
dilutive securities include stock options and warrants. Options to purchase of
2,338,586 and 2,604,493 shares of common stock were not included in the 1998 and
1999 computation of diluted net income (loss) per share, respectively, because
inclusion of such shares would have an anti-dilutive effect on net loss per
share.
Recent Accounting Pronouncements
In June 1998, SFAS No. 133, "Accounting for Derivative Instruments and
Hedging Activities", was issued, which establishes accounting and reporting
standards for derivative instruments, including certain derivative instruments
embedded in other contracts, and for hedging activities. We are required to
adopt SFAS No. 133, as amended by SFAS No. 137, "Accounting for Derivative
Instruments and Hedging Activities -- Deferral of the Effective Dates of FASB
Statement 133," on a prospective basis for interim periods and fiscal years
beginning January 1, 2001. Had we implemented SFAS No. 133 in the current
period, financial position and results of operations would not have been
affected.
3. RELATED PARTIES
We have entered into a number of license, research and development
agreements (the "Agreements") with corporate collaborators. Two agreements were
entered into with Solvay Duphar B.V. ("Solvay") and Wyeth-Ayerst
Pharmaceuticals, a division of American Home Products Corporation
("Wyeth-Ayerst"). Revenue related to these Agreements is included in compound
development revenue. Solvay and Wyeth-Ayerst are related parties as they each
have a representative on our Board of Directors.
4. CASH EQUIVALENTS AND MARKETABLE SECURITIES
The following is a summary of the fair market value of available-for-sale
marketable securities we held at December 31, 1999 and 2000:
DECEMBER 31,
------------------
MATURITY 1999 2000
------------- ------- -------
U.S. Government obligations.............. Within 1 year $ 3,950 $ 6,760
Corporate bonds.......................... Within 1 year 28,263 17,180
------- -------
$32,213 $23,940
======= =======
At December 31, 1999 and 2000, marketable securities are carried at fair
market value. All of our marketable securities are classified as current at
December 31, 1999 and 2000 as the funds are highly liquid and are available to
meet working capital needs and to fund current operations. Gross unrealized
gains and losses on sales of securities for the years ended December 31, 1999
and 2000 were not significant.
32
34
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
5. PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
USEFUL LIFE DECEMBER 31,
ESTIMATED -----------------
(YEARS) 1999 2000
----------- ------- -------
Machinery and equipment........................ 5 $12,423 $17,185
Leasehold improvements......................... 3-15 28,050 26,785
Furniture and fixtures......................... 7 1,651 1,653
Computer equipment............................. 3 6,747 9,097
Construction-in-progress....................... -- 1,980 3,087
------- -------
50,851 57,807
Less -- accumulated depreciation and
amortization................................. 16,758 24,108
------- -------
$34,093 $33,699
======= =======
Assets held under capital leases at December 31, 1999 and 2000 consisted of
$1,900 of machinery and equipment, $1,785 of leasehold improvements, $703 in
computer equipment and $107 of furniture and fixtures. Accumulated amortization
of these assets totaled $4,179 and $4,495 at December 31, 1999 and 2000,
respectively. For the years ended December 31, 1998, 1999 and 2000, amortization
expense related to assets held under capital lease obligations was $1,083, $889
and $316 respectively. Total depreciation and amortization expense for the years
ended December 31, 1998, 1999 and 2000 was $4,620, $7,690 and $7,350,
respectively.
Included in the above amounts of Property and Equipment is interest which
was capitalized in accordance with the provisions of Statement of Financial
Accounting Standards No. 34 ("SFAS 34"), "Capitalization of Interest Costs".
Interest is capitalized by applying an interest rate to the average amount of
accumulated expenditures for an asset during a period which we have borrowings.
Accordingly, we capitalized $440 of interest costs during 1999.
6. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses include the following:
DECEMBER 31,
----------------
1999 2000
------ ------
Accounts payable........................................... $3,636 $1,867
Accrued payroll............................................ 944 1,647
Accrued professional fees.................................. 264 182
Accrued lease termination.................................. 800 150
Other accrued expenses..................................... 75 325
------ ------
$5,719 $4,171
====== ======
7. DEBT
In March 1999, we entered into a term loan agreement with Fleet National
Bank ("Fleet"). The terms of this agreement allow for borrowings up to a maximum
of $15,000 based on 80% of qualifying property and equipment purchases, provided
that we comply with certain covenants, including the maintenance of specified
financial ratios. Borrowings under this facility are classified as either
"Tranche A" (term loans entered into before June 30, 1999) or "Tranche B" (term
loans entered into between July 1, 1999 and June 30, 2000). Principal amounts
due are payable in 16 equal quarterly installments beginning on September 30,
1999 and September 30, 2000 for "Tranche A" and "Tranche B" borrowings,
respectively. Interest payments are made
33
35
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
monthly in arrears beginning on the first day of the month following
commencement of this agreement and accrues at one month LIBOR plus 1.75%. We
entered into an interest rate swap agreement with Fleet primarily to reduce the
impact of changes in interest rates on our term loan agreement. At December 31,
1999, we had two interest rate swaps with notional amounts of $6,200 and $7,800
respectively. Under this agreement, we will pay Fleet interest at weighted
average fixed rates of 7.94% and 8.99%, respectively. Settlement accounting is
used for these interest rate swaps which expire on June 2003 and June 2004,
respectively. The impact on our financial position and results of operations
from likely changes in interest rates is not material, as our hedging of
transactions is limited to these specific liabilities. As of December 31, 2000,
we had total outstanding balances of $3,875 and $6,825, respectively, on our
"Tranche A" and "Tranche B" loans. This facility is collateralized by all of our
property and equipment.
On February 23, 1994, we entered into a lease line agreement with
BankBoston allowing for eligible equipment purchases of up to $8,500. Based on
the terms of the agreement, each lease extends for a period of forty-two equal
monthly payments.
Our principal amounts due under the term loan agreement are as follows:
YEAR ENDING
DECEMBER 31, TRANCHE A TRANCHE B
------------ --------- ---------
2001................................................ $1,550 $1,950
2002................................................ 1,550 1,950
2003................................................ 775 1,950
2004................................................ -- 975
------ ------
Total payments due............................... $3,875 $6,825
====== ======
See note 14 for additional debt incurred subsequent to year end.
8. STOCKHOLDERS' EQUITY
Preferred Stock
We are authorized to issue up to 1.0 million shares of preferred stock. As
of December 31, 1999 and 2000 there were no outstanding shares of preferred
stock. Our Board of Directors will determine the terms of the preferred stock if
and when the shares are issued.
Common Stock
Our amended Certificate of Incorporation authorized the issuance of up to
30 million shares of $0.01 par value common stock.
On November 15, 2000, we completed a follow-on offering of 3,358,000 shares
of common stock at $22.50 per share, which included the underwriters' exercise
of their over-allotment of 438,000 shares of common stock on November 21, 2000.
We realized total net proceeds of approximately $70,867.
At December 31, 2000, we have 4,025,705 common shares reserved for purchase
of common stock under the Employee Stock Purchase Plan and for the exercise of
common stock options pursuant to the Equity Incentive Plan and the 1996
Directors Plan.
9. STOCK OPTION PLANS
During 2000, our stockholders approved an amendment to the 1994 Amended and
Restated Equity Incentive Plan (the "Equity Incentive Plan") increasing the
number of shares of common stock available for awards under the Equity Incentive
Plan to 5,700,000. All shares are awarded at the discretion of our Board of
Directors in a variety of stock-based forms including stock options and
restricted stock. Pursuant to the Equity
34
36
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
Incentive Plan, incentive stock options may not be granted at less than the fair
market value of our common stock at the date of the grant, and the option term
may not exceed ten years. For holders of 10% or more of our voting stock,
options may not be granted at less than 110% of the fair market value of the
common stock at the date of the grant, and the option term may not exceed five
years. Stock appreciation rights granted in tandem with an option shall have an
exercise price not less than the exercise price of the related option. As of
December 31, 2000, no stock appreciation rights have been issued. At December
31, 2000, there were 1,527,617 shares available for future grant under the
Equity Incentive Plan.
Subject to the restrictions above, the Board of Directors is authorized to
designate the options, awards, and purchases under the Equity Incentive Plan,
the number of shares covered by each option, award and purchase, and the related
terms, exercise dates, prices and methods of payment.
Also during 2000, the stockholders approved an amendment to the 1996
Director Stock Option Plan (the "Director Plan") for nonemployee directors
increasing the number of shares of common stock available for awards under the
Director Plan to 190,500. Under this plan, eligible directors are automatically
granted once a year, at our annual meeting of stockholders, options to purchase
3,500 shares of common stock, which are exercisable on the date of grant. Upon
initial election of an eligible director, options to purchase 7,500 shares of
common stock will be granted which will become exercisable in three equal annual
installments commencing on the date of our next annual stockholders' meeting
held after the date of grant. All options granted pursuant to the Director Plan
have a term of ten years with exercise prices equal to fair market value on the
date of grant. Through December 31, 2000, options to purchase 130,500 shares of
common stock have been granted under this plan of which 108,000 shares are
currently exercisable. As of December 31, 2000, 60,000 shares are available for
future grant.
During 1999 and 2000, we issued 45,500 and 25,500 options, respectively, to
certain members of our Scientific Advisory Board (SAB) under the Equity
Incentive Plan. In 1999, 18,000 shares were cancelled. Compensation expense in
1999 and 2000 was $486 and $660, respectively. Also during 2000, compensation
expense of $220 was recorded for employees who received non-qualified stock
options at below fair market value on the date of grant. The remaining deferred
compensation of $181 was recorded at December 31, 2000 and is being amortized as
compensation expense over the vesting period of the options.
We apply APB No. 25 and related interpretations in accounting for employee
grants under the Equity Incentive Plan. Had compensation cost been determined
based on the estimated, value of options at the grant date consistent with the
provisions of SFAS No. 123, our pro forma net loss, pro forma basic net loss per
share and diluted net loss per share would have been as follows:
DECEMBER 31,
-----------------------------------
1998 1999 2000
-------- ------------ -------
Pro forma net loss........................ $(13,217) $(21,746) $(3,321)
Pro forma basic and diluted net loss per
share................................... $ (1.10) $ (1.73) $ (0.24)
For the purposes of pro forma disclosure, the estimated value of each
employee and nonemployee option grant was calculated on the date of grant using
the Black-Scholes option-pricing model. The Black-Scholes option-pricing model
was developed for use in estimating the fair value of traded options that have
no vesting restrictions and are fully transferable. In addition, option-pricing
models require the use of highly subjective assumptions, including the expected
stock price volatility. Because our employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective assumptions can materially affect the fair value estimates, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock-based compensation. The
model was calculated using the following weighted-average assumptions: no
dividend yield for all years; 75% volatility for 1998 and 1999, 95% for 2000;
risk-free interest rates of 6.0% in 1998, 5.46% in 1999 and 6.0% in 2000;
expected lives of 4 years in 1998, 1999 and 2000 for options granted.
35
37
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
Option activity under the Plans for the three years ended December 31, 2000
was as follows:
WEIGHTED
AVERAGE
NUMBER EXERCISE
STOCK OPTIONS OF SHARES PRICE
- ------------- ---------- --------
Outstanding at December 31, 1997...................... 2,111,252 $ 9.87
Granted............................................... 1,606,265 9.06
Exercised............................................. (134,639) 5.90
Cancelled............................................. (1,244,292) 15.25
----------
Outstanding at December 31, 1998...................... 2,338,586 6.68
Granted............................................... 1,050,755 4.65
Exercised............................................. (536,473) 1.67
Cancelled............................................. (243,125) 7.36
----------
Outstanding at December 31, 1999...................... 2,609,743 6.83
Granted............................................... 597,658 18.05
Exercised............................................. (758,403) 7.39
Cancelled............................................. (182,112) 8.11
----------
Outstanding as of December 31, 2000................... 2,266,886 $ 9.50
==========
Exercisable at December 31, 2000...................... 918,206 $ 8.22
==========
Weighted average estimated value of options granted
during the year ended December 31, 2000............. $12.60
The following table summarizes information about options outstanding at
December 31, 2000:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
----------------------------------------- ------------------------
WEIGHTED
NUMBER AVERAGE WEIGHTED EXERCISABLE WEIGHTED
OUTSTANDING AT REMAINING AVERAGE AS OF AVERAGE
DECEMBER 31, CONTRACTUAL EXERCISE DECEMBER 31, EXERCISE
RANGE OF EXERCISE PRICES 2000 LIFE PRICE 2000 PRICE
- ------------------------ -------------- ----------- -------- ------------ --------
$ 0.0000 -- 2.8000.............. 32,500 4.7 $ 0.90 32,500 $ 0.90
2.8001 -- 5.6000.............. 1,250,392 7.9 4.73 490,323 4.78
5.6001 -- 8.4000.............. 205,885 6.5 6.51 153,884 6.39
8.4001 -- 11.2000.............. 54,000 7.2 10.56 29,500 10.82
11.2001 -- 14.0000.............. 7,500 5.9 12.00 7,500 12.00
14.0001 -- 16.8000.............. 40,600 6.6 15.34 39,975 15.36
16.8001 -- 19.6000.............. 366,259 8.3 17.88 97,024 17.76
19.6001 -- 22.4000.............. 249,750 7.9 20.20 50,000 20.91
22.4001 -- 25.2000.............. 60,000 9.0 23.07 17,500 22.94
--------- -------
2,266,886 7.8 $ 9.50 918,206 $ 8.22
========= =======
On September 8, 1998, we determined that certain stock options issued to
our employees had an exercise price significantly higher than the fair market
value of our common stock. In light of our conclusions that such options were
not providing the desired incentive, we provided employees with the opportunity
to exchange options previously granted to them under the Equity Incentive Plan
on or after June 25, 1996 for new options ("the Replacement Options") to
purchase the same number of shares of common stock at an exercise price of
$4.875 per share, the then fair market value of our common stock. A total of
985,059 options were exchanged. Employees (other than those individuals
designated as "officers" by the Company, including those officers
36
38
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
subject to Section 16 of the Securities Exchange Act of 1934) were given the
choice of retaining their existing options, with the original vesting schedule,
or accepting the Replacement Options, with a vesting schedule extended by one
year.
Employee Stock Purchase Plan
In 1996, the stockholders adopted the 1996 Employee Stock Purchase Plan
(the "Purchase Plan"). This plan enables eligible employees to exercise rights
to purchase our common stock at 85% of the fair market value of the stock on the
date the right was granted or the date the right is exercised, whichever is
lower. Rights to purchase shares under the Purchase Plan are granted by the
Board of Directors. The rights are exercisable during a period determined by the
Board of Directors; however, in no event will the period be longer than
twenty-seven months. The Purchase Plan is available to substantially all
employees, subject to certain limitations. At December 31, 2000, 311,303 shares
have been purchased pursuant to the Purchase Plan. In May 1999 the Board of
Directors approved an increase from 120,000 shares reserved to 420,000 shares
reserved of common stock for purchase under the Purchase Plan. This increase was
approved at the May 2000 annual meeting of stockholders.
10. INCOME TAXES
There is no current or deferred tax expense for the years ended December
31, 1998, 1999 and 2000.
The deferred tax consequences of temporary differences in reporting items
for financial statement and income tax purposes are recognized, if appropriate.
Realization of the future tax benefits related to the deferred tax assets is
dependent on many factors, including our ability to generate taxable income
within the net operating loss carryforward period. Management has considered
these factors in reaching its conclusion as to the valuation allowance for
financial reporting purposes. The income tax effect of temporary differences
comprising the deferred tax assets and deferred tax liabilities on the
accompanying balance sheets is a result of the following:
DECEMBER 31,
--------------------------------
1998 1999 2000
-------- -------- --------
Deferred tax assets:
Preoperating costs capitalized for tax
purposes.............................. $ 210 $ 189 $ 164
Net operating loss carryforwards......... 7,068 6,671 11,417
Tax credit carryforwards................. 2,324 3,773 6,790
Equity based compensation................ 286 486 830
Book depreciation in excess of tax....... 411 1,361 411
Reserves and accruals.................... -- 329 138
Deferred revenue......................... -- 6,362 4,523
Other.................................... 39 18 6
-------- -------- --------
$ 10,338 $ 19,189 $ 24,279
Deferred tax liabilities:
Valuation allowance........................ (10,338) (19,189) (24,279)
-------- -------- --------
Net deferred tax assets.................. $ -- $ -- $ --
======== ======== ========
We have provided a full valuation allowance for the deferred tax assets, as
the realization of these future benefits is not sufficiently assured as of the
end of each related year. If we achieve profitability, the deferred tax assets
will be available to offset future income tax liabilities and expense. Of the
$24,279 valuation allowance at December 31, 2000, $5,600 relates to deductions
for disqualifying dispositions and non-qualified stock options that will be
credited to paid in capital, if realized.
37
39
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
A reconciliation between the statutory federal income tax rate (34%) and
the effective rate of income tax expense for each of the three years during the
period ended December 31, 2000 follows:
YEAR ENDED DECEMBER 31,
-----------------------------
1998 1999 2000
------- ------- -------
Income tax benefit (expense) at statutory
rate........................................ $ 2,262 $ 6,102 $(1,311)
State tax benefit (expense), net.............. 399 1,076 (390)
Losses and credits without current tax
benefit..................................... (2,650) (7,170) --
Utilization of net operating loss
carryforwards............................... -- -- 1,698
Other......................................... (11) (8) 3
------- ------- -------
Tax Provision............................... $ -- $ -- $ --
======= ======= =======
We have available net operating loss carryforwards of approximately $29,900
for tax purposes to offset future taxable income. The net operating loss
carryforwards expire at various dates through 2020. Federal and state tax credit
carryforwards of approximately $3,600 and $4,800 respectively, expire at various
dates through 2020. Under the Internal Revenue Code, certain substantial changes
in our ownership could result in an annual limitation on the amount of net
operating loss and tax credit carryforwards which can be utilized in future
years.
11. COMMITMENTS
Leases
We lease facilities and equipment under noncancelable operating and capital
leases. The future minimum lease commitments under these leases are as follows:
YEAR ENDING OPERATING
DECEMBER 31, LEASES
- ------------ ---------
2001........................................................ $1,122
2002........................................................ 839
2003........................................................ 839
2004........................................................ 839
2005........................................................ 732
thereafter.................................................. 348
------
Total minimum lease payments.............................. $4,719
======
Rent expense under noncancelable operating leases was approximately $1,105,
$1,420 and $2,228 for the years ended December 31, 1998, 1999 and 2000,
respectively.
Our research facilities also include approximately 56,000 square feet of
laboratory and office space in Medford, Massachusetts, the majority of which is
dedicated to the Pfizer collaboration. We lease these facilities under two lease
agreements, one of which expires on July 30, 2005 and one of which expires on
July 30, 2006. We sublease these facilities pursuant to three sublease
agreements. The monthly cost of these leases is entirely offset by our income
from these subleases.
See note 14 for additional commitments incurred subsequent to year-end.
12. CONCENTRATION OF CREDIT RISK
Revenues from five of our customers accounted for 12%, 13%, 14%, 16% and
30% of total revenues during 1998. Revenues from five of our customers accounted
for 12%, 13%, 16%, 20% and 30% of total revenues
38
40
ARQULE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- CONTINUED
during 1999. Revenues from five of our customers accounted for 60%, 12%, 11%, 7%
and 4% of total revenues during 2000. Three of our customers accounted for 21%,
31% and 41% of our accounts receivable balance at December 31, 1998 and 23%, 31%
and 46% of our accounts receivable balance at December 31, 1999. Four of our
customers accounted for 42%, 32%, 12%, and 11% of our accounts receivable
balance at December 31, 2000. We do not require collateral on accounts
receivable balances.
13. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
FIRST SECOND THIRD FOURTH
QUARTER QUARTER QUARTER QUARTER
------- ------- ------- -------
2000
Net revenues........................................ $10,388 $12,084 $13,785 $14,039
Gross profit........................................ 4,982 6,767 8,744 8,460
Net income (loss)................................... (1,342) 609 2,978 1,610
Net income (loss) per share, (diluted).............. $ (0.10) $ 0.04 $ 0.20 $ 0.10
1999
Net revenues........................................ $ 4,012 $ 4,591 $ 4,860 $ 5,119
Gross profit........................................ 338 672 768 (653)
Net income (loss)................................... (3,966) (3,594) (3,657) (6,216)
Net income (loss) per share, (diluted).............. $ (0.32) $ (0.29) $ (0.29) $ (0.49)
14. SUBSEQUENT EVENTS
In January 2001, we acquired Camitro Corporation, a privately-held
predictive modeling company based in Menlo Park, California. Under the terms of
the merger agreement, we issued 3,398,816 shares of our common stock and $1,733
in cash in exchange for all of Camitro's outstanding shares and the assumption
of all of Camitro's outstanding stock options and warrants. The merger
transaction was valued at $84,700 based on our share price on the measurement
date for the merger. The transaction will be accounted for as a purchase
transaction.
In November 2000, we exercised our options to purchase our building and the
adjacent lot in Woburn, Massachusetts and in March 2001 we closed the
transaction. The total consideration paid for the properties was $20,512, of
which $18,200 represented the purchase price for the entire building and the
land on which it sits and $2,312 represented the purchase price for the adjacent
lot. The purchase price was determined through an arms-length negotiation with
Metro North Corporate Center LLC and Metro North Corporate Center LLC II, which
are unaffiliated with us or any of our directors or executive officers.
We paid $4,512 in cash and granted a mortgage for the remainder of the
purchase price through an extension of our existing term loan with Fleet Bank
dated as of March 18, 1999, with an initial interest rate of 6.95%. The land
upon which our facility sits is approximately 7.2 acres, including a parking
lot, while the adjacent parcel of land represents approximately 5 acres. We plan
to continue to use our facility in its current capacity and may develop the
adjacent parcel at a presently undetermined time in the future.
39
41
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
A portion of the response to this item is contained in part under the
caption "Executive Officers and Directors of the Registrant" in Part I, Item 1A
of this Annual Report on Form 10-K.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Our executive officers and directors are required under Section 16(a) of
the Exchange Act to file reports of ownership and changes in ownership of our
securities with the Securities and Exchange Commission. Copies of those reports
must also be furnished to us.
Based solely on a review of the copies of reports furnished to us and
written representations that no other reports were required, we believe that
during our 2000 fiscal year, our directors, executive officers and 10%
beneficial owners complied with all application Section 16(a) filing
requirements, except that two purchases of common stock by Ms. Avakian and her
spouse in August 2000, totaling 500 shares, were reported on a Statement of
Changes in Beneficial Ownership on Form 4 after the date on which such filing
was required for such transactions.
ITEM 11. EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The following table summarizes the compensation paid to or earned during
the fiscal year by our Chief Executive Officer and our four most highly paid
executive officers whose salary and bonus exceeded $100,000 during the fiscal
year ended December 31, 2000. We refer to these persons as the named executive
officers.
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
-------------------------------------------- ------------
OTHER ANNUAL SECURITIES
COMPENSATION UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY($) BONUS ($) OPTIONS(#) COMPENSATION($)
- --------------------------- ---- --------- -------- ------------ ------------ ---------------
Dr. Stephen A. Hill(1).................. 2000 $328,462 $125,000(3) $ 15,098(4) 40,000 --
President and Chief Executive Officer 1999 $213,462(2) $100,000(3) $102,581(4) 320,000 --
Philippe Bey, Ph.D.(5).................. 2000 $245,686 $ 84,000(7) $ 68,693(8) 20,000 --
Senior Vice President of Research 1999 $ 98,616(6) -- $ 15,539(8) 170,000 --
and Development and Chief Scientific
Officer
Michael D. Rivard....................... 2000 $169,208 $ 42,500(9) -- -- --
Vice President, Legal, and General 1999 $149,023 $ 10,000(9) -- 12,927 --
Counsel and Assistant Secretary 1998 $138,997 -- -- 34,531 --
James Kyranos, Ph.D. ................... 2000 $172,264 $ 35,640(10) -- -- --
Vice President of Systems 1999 $154,308 $ 10,000(10) -- 22,509 --
Technologies 1998 $128,077 -- -- 34,901 --
John Sorvillo, Ph.D. ................... 2000 $170,423 $ 34,000(11) -- -- --
Vice President of Business 1999 $147,734 $ 10,000(11) -- 22,509 --
Development 1998 $140,543 -- -- 12,099 --
- ---------------
(1) Dr. Hill commenced employment with us in April 1999. Terms of his
employment are described under "Executive Employment Agreements."
(2) Dr. Hill joined us as President and Chief Executive Officer effective April
1, 1999 and this amount represents a pro rata portion of his 1999 annual
base salary of $300,000.
40
42
(3) This amount consists of Dr. Hill's expected 2000 bonus to be paid in 2001
and 1999 bonus paid in 2000.
(4) Pursuant to his employment agreement, we paid Dr. Hill $100,000, in 1999 as
compensation for certain warrants he would have been entitled to receive
had he remained with his prior employer. Dr. Hill was reimbursed for
$15,098 and $2,581 of relocation expenses incurred by him during the fiscal
year ended December 31, 2000 and 1999, respectively in connection with
joining ArQule.
(5) Dr. Bey commenced employment with us in August 1999. Terms of his
employment are described under "Executive Employment Agreements."
(6) Dr. Bey joined us as Senior Vice President of Research and Development and
Chief Scientific Officer, August 16, 1999 and this amount represents a pro
rata portion of his 1999 annual base salary of $240,000.
(7) Pursuant to his employment agreement, we paid Dr. Bey a bonus of $60,000 on
his anniversary of his employment, upon achievement of certain milestones.
Also, $24,000 was paid to Dr. Bey in 2001 for an additional 2000 bonus.
(8) This amount consists of reimbursement of relocation and temporary living
expenses incurred by Dr. Bey during the fiscal year ended December 31, 2000
and 1999 in connection with joining ArQule.
(9) This amount consists of Mr. Rivard's 2000 and 1999 bonuses paid in 2001 and
2000, respectively.
(10) This amount consists of Dr. Kyranos' 2000 and 1999 bonuses paid in 2001 and
2000, respectively.
(11) This amount consists of Dr. Sorvillo's 2000 and 1999 bonuses paid in 2001
and 2000, respectively.
STOCK OPTION GRANTS IN LAST FISCAL YEAR
The following table sets forth certain information regarding options
granted during the fiscal year ended December 31, 2000 by us to the named
executive officers:
POTENTIAL REALIZABLE
VALUE OF ASSUMED
NUMBER OF PERCENT OF ANNUAL RATES OF STOCK
SECURITIES TOTAL OPTIONS FAIR MARKET PRICE APPRECIATION FOR
UNDERLYING GRANTED EXERCISE OR VALUE ON OPTION TERM(1)
OPTIONS EMPLOYEES IN BASE PRICE GRANT DATE EXPIRATION -----------------------------
GRANTED(#) FISCAL YEAR ($/SHARE) ($/SHARE) DATE 0%($) 5%($) 10%($)
---------- ------------- ----------- ----------- ---------- ----- -------- ----------
Dr. Stephen A. Hill..... 40,000(2) 6.69% $20.0625(3) -- 3/16/2010 -- $504,688 $1,278,978
Philippe Bey, Ph.D. .... 20,000(4) 3.35% $ 19.875(3) -- 9/15/2010 -- $249,986 $ 633,513
Michael D. Rivard....... -- -- -- -- -- -- -- --
James Kyranos, Ph.D. ... -- -- -- -- -- -- -- --
John M. Sorvillo, --
Ph.D. ................ -- -- -- -- -- -- --
- ---------------
(1) The dollar amounts under these columns are the result of calculations at 0%,
5% and 10% rates set by the Securities and Exchange Commission and,
therefore, are not intended to forecast possible future appreciation, if
any, in the price of the underlying common stock.
(2) These options were granted under our Amended and Restated 1994 Equity
Incentive Plan and become exercisable as to 25% of the shares on each of
March 16, 2001, 2002, 2003 and 2004.
(3) The exercise price of these options is equal to 100% of the fair market
value of our common stock on the date the options were granted, as
determined by our Compensation Committee.
(4) These options were granted under our Amended and Restated 1994 Equity
Incentive Plan and become exercisable as to 25% of the shares on each of
September 15, 2001, 2002, 2003, and 2004.
41
43
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES
The following table sets forth certain information concerning exercisable
and unexercisable stock options held by the named executive officers as of
December 31, 2000.
NUMBER OF SECURITIES
UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS
AT FISCAL YEAR-END(#) AT FISCAL YEAR-END($)(2)
SHARES ACQUIRED VALUE --------------------------- ---------------------------
ON EXERCISE(#) REALIZED($)(1) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
--------------- -------------- ----------- ------------- ----------- -------------
Dr. Stephen A. Hill...... -- $ -- 80,000 280,000 $2,190,000 $7,047,500
Philippe Bey, Ph.D. ..... -- $ -- 42,500 147,500 $1,166,073 $3,740,718
Michael D. Rivard........ -- $ -- 63,458 34,000 $1,137,070 $ 744,528
James Kyranos, Ph.D. .... 2,500 $19,656 37,744 25,000 $1,013,803 $ 686,555
John M. Sorvillo,
Ph.D. ................. -- $ -- 86,083 17,500 $2,143,398 $ 479,368
- ---------------
(1) Based on the difference between the option exercise price of options and the
closing price of the underlying common stock on the date of exercise.
(2) Based on the difference between the exercise price of options and the
closing price of the underlying shares of common stock on December 29, 2000
as reported by the Nasdaq National Market ($32.00).
EXECUTIVE EMPLOYMENT AGREEMENTS
We currently have an employment agreement with Dr. Hill and Dr. Bey.
We entered into an employment agreement with Dr. Hill, agreeing to employ
him as our President and Chief Executive Officer, effective April 1, 1999, at an
initial annual base salary of $300,000. Pursuant to the employment agreement,
Dr. Hill was granted options, which vest over four years, to acquire 320,000
shares of common stock at $4.625 per share. The employment agreement provides
that we pay Dr. Hill $100,000 for certain warrants he would have been entitled
to had he remained with his prior employer. The agreement also requires (i) the
payment of an annual bonus of up to $100,000 upon the achievement of certain
milestones, which will be determined by our board of directors, and (ii) the
payment of certain moving and relocation expenses. The agreement provides for
continued employment until terminated by either party. If Dr. Hill is terminated
without cause, as defined in the agreement, we will be required to make a one
time payment to him equal to his annual base salary and to continue to provide
him with insurance and other benefits for a period of one year.
We entered into an employment agreement with Dr. Bey, agreeing to employ
him as our Senior Vice President of Research and Development and Chief
Scientific Officer, effective August 1999, at an initial annual base salary of
$240,000. Pursuant to the employment agreement, Dr. Bey was granted options,
which vest over four years, to acquire 170,000 shares of common stock at $4.56
per share. The agreement also requires (i) the payment of an annual bonus of up
to $60,000, upon the achievement of certain milestones, and (ii) the payment of
certain moving and relocation expenses. The agreement provides for continued
employment until terminated by either party. If Dr. Bey is terminated without
cause, as defined in the agreement, we will be required to make a one time
payment to him equal to his annual base salary and to continue to provide him
with insurance and other benefits for a period of one year.
Upon our acquisition of Camitro in January 2001, we entered into an
employment agreement with Dr. Selick, agreeing to employ him as the President
and Chief Executive Officer of Camitro Corporation effective January 29, 2001,
at an annual salary of $250,000. The agreement also provides for the payment of
an annual bonus upon the one year anniversary of employment. If Dr. Selick is
terminated by us for cause, or if he leaves for Good Reason, as defined in the
agreement, then we will be required to (i) make a one time payment to him equal
to his annual base salary, (ii) provide him with insurance and other benefits
for a period of one year, and (iii) accelerate the vesting of all of his options
and restricted stock that he received in our acquisition of Camitro. The
agreement also requires Dr. Selick to refrain from competing with us and from
soliciting our customers and employees during his employment and for a period of
one year thereafter.
42
44
DIRECTOR COMPENSATION
Our directors do not receive cash compensation for their services as
directors. However, all directors who are not employees are currently eligible
to participate in the Amended and Restated 1996 Director Stock Option Plan.
The Director Stock Option Plan provides that each non-employee director who
is serving as a director prior to and immediately after any annual meeting of
stockholders (whether or not a director is being re-elected) receives an
automatic grant of an option to purchase 3,500 shares of our common stock. This
option is fully exercisable on the date of grant. In addition, upon the initial
election to the board, each non-employee director receives an automatic grant of
an option to purchase 7,500 shares of common stock. This option becomes
exercisable with respect to 2,500 shares on the date of our next annual meeting
of stockholders and each of the next two annual meetings of stockholders
thereafter, so long as the director remains in office. The options have a term
of ten years and an exercise price equal to the closing price of the common
stock as reported by the Nasdaq National Market on the last trading day prior to
the date of grant. All questions of interpretation with respect to the Director
Stock Option Plan and the options granted thereunder are determined by the board
of directors. The Director Stock Option Plan currently authorizes the grant of
stock options to purchase up to a maximum of 190,500 shares of common stock
(subject to adjustments for stock splits and similar capital changes).
Mr. Elia received an option to purchase 10,000 shares of common stock upon
his election to the board in September 2000, which includes the standard option
to purchase 7,500 shares as well as an additional option to purchase 2,500
shares that vests as to one-third of the shares on each anniversary of date of
grant. Ms. Avakian and Mr. Ha-Ngoc each received an option to purchase 7,500
shares of common stock upon their election to the board in March 2000 and each
received an option to purchase 3,500 shares of common stock in May 2000. Dr.
Cautreels, Dr. Gage and Dr. Rosenblatt each received grants of options to
purchase 3,500 shares of common stock in May 2000.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
In 2000, the Compensation Committee consisted of Mr. Stephen Dow (until
July 25, 2000), Dr. Cautreels, Dr. Gage and Ms. Avakian, who became a member in
March 2000. None of the members of the Compensation Committee has been an
officer or employee of ArQule.
On March 5, 1998, Dr. Gage, was appointed the President of Wyeth-Ayerst
Research, a division of American Home Products Corporation, after the merger of
American Home Products and Genetics Institute, Inc., of which Mr. Gage was
President. We entered into a collaborative agreement with Wyeth-Ayerst in July
1997, pursuant to which Wyeth-Ayerst subscribed to our Mapping Array(TM) Program
and has committed to a minimum number of Directed Array(TM) Programs.
Wyeth-Ayerst made a $2 million equity investment in ArQule in June 1998. The
total value of this agreement is up to $26.2 million in committed payments. In
addition, Wyeth-Ayerst has agreed to pay us development milestones and royalties
from the sales of products resulting from the collaboration.
Dr. Cautreels has been the Global Head of Research and Development of
Solvay Pharmaceuticals B.V. since May 1998, and has been one of our directors
since September 1999. In November 1995, we entered into a five-year agreement
with Solvay Duphar B.V., which was superseded by an amended and restated
agreement with Solvay Pharmaceuticals B.V. in January 2001 and extends through
December 31, 2003. We received a total of $18.1 million under the original
agreement. Solvay is committed to make $2.5 million in additional payments and
has also agreed to make additional payments if we achieve certain development
milestones and to pay royalties on sales of any drugs that result from the
relationship. In connection with this collaboration, an affiliate of Solvay,
Physica B.V., made a $7 million equity investment with us.
43
45
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SHARE OWNERSHIP
The following table and footnotes set forth certain information regarding
the beneficial ownership of our common stock as of March 9, 2001 by (i) persons
known by us to be beneficial owners of more than 5% of the common stock, (ii)
our named executive officers and current executive officers, (iii) our directors
and nominee for election as director, and (iv) all current executive officers
and directors as a group.
SHARES BENEFICIALLY
OWNED(1)
--------------------
NUMBER PERCENT
--------- -------
5% STOCKHOLDERS
Alloy Ventures(2)........................................... 1,267,775 6.28%
480 Cowper Street, 2nd Floor
Palo Alto, California 94301
OrbiMed Advisors LLC(3)..................................... 1,130,000 5.60%
767 Third Avenue, 6th Floor
New York, New York 10010
The PNC Financial Services Group, Inc.(4)................... 1,074,650 5.32%
One PNC Plaza, 249 Fifth Avenue,
Pittsburgh, Pennsylvania 15222-2707
DIRECTORS AND EXECUTIVE OFFICERS
Laura Avakian(5)............................................ 12,500 *
Werner Cautreels, Ph.D.(6).................................. 15,500 *
Ariel Elia(7)............................................... 16,000 *
L. Patrick Gage, Ph.D.(8)................................... 28,000 *
Tuan Ha-Ngoc(9)............................................. 12,000 *
Michael Rosenblatt, M.D.(10)................................ 21,500 *
Philippe Bey(11)............................................ 42,845 *
David C. Hastings(12)....................................... 15,000 *
Stephen A. Hill(13)......................................... 173,236 *
James Kyranos, Ph.D.(14).................................... 53,076 *
Michael D. Rivard(15)....................................... 83,405 *
Harold E. Selick............................................ 189,890 *
John Sorvillo(16)........................................... 92,270 *
All current directors and executive officers as a group (9
persons)(17).............................................. 526,471 2.60%
- ---------------
* Indicates less than 1%
(1) The persons and entities named in the table have sole voting and investment
power with respect to the shares beneficially owned by them, except as
noted below.
(2) These shares include 301,413 shares beneficially owned by Asset Management
Associates, 1996, L.P., a Delaware limited partnership, and by its general
partner AMC Partners 96, L.P., a Delaware limited partnership. These shares
also include 43,950 shares owned by AMA98 Partners, L.P., a Delaware
limited partnership, 726,210 shares owned by AMA98 Ventures, L.P., a
Delaware limited partnership, 87,144 shares owned by AMA98 Corporate, L.P.,
a Delaware limited partnership, and 109,036 shares owned by AMA98
Investors, L.P., a Delaware limited partnership, and by Alloy Ventures
1998, LLC, their general partner. Douglas E. Kelly, John F. Shoch, Craig C.
Taylor, and Tony Di Bona are each general partners of AMC Partners 96,
L.P., and are each managing members of AlloyVentures 1998, LLC, and may
therefore be deemed to have investment and voting control over the shares
listed. Each person disclaims beneficial ownership of the shares, except to
the extent of their pecuniary interest therein. Based on shares issued by
us in connection with our acquisition of Camitro on January 29, 2001.
44
46
(3) These shares are beneficially owned by OrbiMed Advisors Inc., a corporation
organized under the laws of the British Virgin Islands, OrbiMed Advisors
LLC, a Delaware limited liability company, Caduceus Capital Trust, a trust
organized under the laws of Bermuda, Caduceus Capital II, L.P., a Delaware
limited partnership, PaineWebber Eucalyptus Fund, LLC, a Delaware limited
liability company, and PaineWebber Eucalyptus Fund, Ltd., a company
organized under the laws of the Cayman Islands. Based on the Schedule 13G
filed by OrbiMed Advisors LLC with the SEC on September 22, 2000.
(4) These shares are beneficially owned by The PNC Financial Services Group,
Inc. ("PNC"), a Pennsylvania corporation, PNC Bancorp, Inc., a Delaware
corporation, and a wholly owned subsidiary of PNC, PNC Bank, National
Association, a wholly owned subsidiary of PNC Bancorp, Inc., BlackRock
Advisors, Inc., a Delaware corporation, and a wholly owned subsidiary of
BlackRock, Inc., and BlackRock Financial Management, Inc. a Delaware
corporation, and a wholly owned subsidiary of BlackRock Advisors, Inc.
Based on the Schedule 13G filed by PNC with the SEC on February 14, 2001.
(5) Consists of (i) 500 shares of common stock, (ii) 12,000 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(6) Consists solely of 15,500 shares of common stock subject to options that
are presently exercisable or will become exercisable within sixty (60) days
of April 3, 2001.
(7) Consists of (i) 10,000 shares of common stock, (ii) 6,000 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(8) Consists of (i) 10,000 shares of common stock and (ii) 18,000 shares of
common stock subject to options that are presently exercisable or will
become exercisable within sixty (60) days of April 3, 2001.
(9) Consists solely of 12,000 shares of common stock subject to options that
are presently exercisable or will become exercisable within sixty (60) days
of April 3, 2001.
(10) Consists solely of 21,500 shares of common stock subject to options that
are presently exercisable or will become exercisable within sixty (60) days
of April 3, 2001.
(11) Consists of (i) 345 shares of common stock, (ii) 42,500 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(12) Consists solely of 15,000 shares of common stock subject to options that
are presently exercisable or will become exercisable within sixty (60) days
of April 3, 2001.
(13) Consists of (i) 3,236 shares of common stock, (ii) 170,000 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(14) Consists of (i) 5,332 shares of common stock, (ii) 47,744 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(15) Consists of (i) 4,947 shares of common stock, (ii) 83,405 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(16) Consists of (i) 1,187 shares of common stock, (ii) 91,083 shares of common
stock subject to options that are presently exercisable or will become
exercisable within sixty (60) days of April 3, 2001.
(17) Includes 312,500 shares of common stock subject to options that are
presently exercisable or will become exercisable within sixty (60) days of
April 3, 2001. See footnotes (5) through (13), as well as Harold E.
Selick's holdings.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
See "Compensation Committee Interlocks and Insider Participation" under the
caption "Executive Compensation" in Part III, Item 11 of this Annual Report on
Form 10-K.
45
47
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULE AND REPORTS ON FORM 8-K
(a) 1. FINANCIAL STATEMENTS
The financial statements are listed under Item 8 of this report.
2. FINANCIAL STATEMENT SCHEDULES
The financial statement schedules listed under Item 8 of this
report are omitted because they are not applicable or required
information and are shown in the financial statements of the
footnotes thereto.
(b) REPORTS ON FORM 8-K DURING FOURTH QUARTER OF 2000
On October 17, 2000, we filed on Form 8-K to file an Amendment No. 1 to
a Compound Supply and License Agreement by and between ArQule, Inc. and
R.W. Johnson Pharmaceuticals Research Institute.
46
48
(c) EXHIBITS
EXHIBIT
NO. DESCRIPTION
- ------- -----------
2.1 Agreement and Plan of Merger among the Company, Camitro
Acquisition Corporation, Camitro Corporation, and certain
stockholders of Camitro Corporation dated as of January 16,
2001. Previously filed as Exhibit 2.1 to the Company's
Current Report on Form 8-K (File No. 000-21429). Filed with
the Commission on February 1, 2001 and incorporated herein
by reference.
3.1 Amended and Restated Certificate of Incorporation of the
Company. Filed as Exhibit 3.1 to the Company's Registration
Statement on Form S-1 (File No. 333-22945) and incorporated
herein by reference.
3.2 Amended and Restated By-laws of the Company. Filed as
Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
4.1 Specimen Common Stock Certificate. Filed as Exhibit 4.1 to
the Company's Registration Statement on Form S-1 (File No.
333-11105) and incorporated herein by reference.
10.1* Amended and Restated 1994 Equity Incentive Plan, as ended
through April 8, 1998. Filed as Exhibit 10.1 to the
Company's Quarterly Report on Form 10-Q for the quarter
amended June 30, 1998 (File No. 000-21429) and incorporated
herein by reference.
10.2* Amended and Restated 1996 Employee Stock Purchase Plan.
Filed as Exhibit 10.1 to the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 1999 (File No.
000-21429) and incorporated herein by reference.
10.3* Amended and Restated 1996 Director Stock Option Plan. Filed
As Exhibit 10.3 to the Company's Annual Report on Form 10-K
For the fiscal year ended December 31, 1997 filed with the
Commission on March 17, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.4 Form of Indemnification Agreement between the Company and
its directors. Such agreements are materially different only
as to the signing directors and the dates of execution.
Filed as Exhibit 10.4 to the Company's Registration
Statement on Form S-1 (File No. 333-11105) and incorporated
herein by reference.
10.5 Lease Agreement, dated July 27, 1995, between the Company
and Cummings Properties Management, Inc. as amended. Filed
as Exhibit 10.7 to the Company's Registration Statement on
Form S-1 (File No. 333-11105) and incorporated herein by
reference.
10.6+ Research, Development and License Agreement between the
Company and Solvay Duphar B.V. dated November 2, 1995. Filed
as Exhibit 10.14 to the Company's Registration Statement on
Form S-1 (File No. 333-11105) and incorporated herein by
reference.
10.7+ Research & Development and License Agreement between the
Company and Abbott Laboratories dated June 15, 1995, as
amended. Filed as Exhibit 10.15 to the Company's
Registration Statement on Form S-1 (File No. 333-11105) and
incorporated herein by reference.
10.8* Adoption Agreement for Fidelity Management and Research
Company (the Company's 401(k) plan). Filed as Exhibit 10.18
to the Company's Registration Statement on Form S-1 (File
No. 333-11105) and incorporated herein by reference.
10.9+ Research and License Agreement between the Company and Roche
Bioscience dated September 13, 1996. Filed as Exhibit 10.19
to the Company's Registration Statement on Form S-1 (File
No. 333-11105) and incorporated herein by reference.
47
49
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.10+ Array Delivery and Testing Agreement between the Company and
Monsanto Company dated as of December 23, 1996. Filed as
Exhibit 10.20 to the Company's Registration Statement on
Form S-1 (File No. 333-22945) and incorporated herein by
reference.
10.11+ Amendment No. 2 to Research & Development License Agreement
between the Company and Abbott Laboratories dated as of
December 24, 1996. Filed as Exhibit 10.21 to the Company's
incorporated herein by reference.
10.12 Lease Agreement, dated December 20, 1996 between the Company
and Cummings Property Management, Inc. Filed as Exhibit
10.22 to the Company's Registration Statement on Form S-1
(File No. 333-22945) and incorporated herein by reference.
10.13+ Research and License Agreement between the Company and
American Home Products Corporation acting through its
Wyeth-Ayerst Research Division dated July 3, 1997. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1997 (File No. 000-21249) and
incorporated herein by reference.
10.14+ Second Amendment to Option Agreement and Research and
Development Agreement between the Company and Amersham
Pharmacia Biotech AB dated September 23, 1996. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1997 (File No.
000-21429) and incorporated herein by reference.
10.15+ Third Amendment to Option Agreement and Research and
Development Agreement between the Company and Amersham
Pharmacia Biotech AB dated June 24, 1997. Filed as Exhibit
10.2 to the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 1997 (File No. 000-21429) and
incorporated herein by reference.
10.16+ Research and Development Agreement between the Company and
Sankyo Co., Ltd. dated November 1, 1997. Filed as Exhibit
10.29 to the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1997, filed with the
Commission on March 17, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.17+ Amendment No. 3 to Research & Development and License
Agreement between the Company and Abbott Laboratories dated
December 23, 1997. Filed as Exhibit 10.30 to the Company's
Annual Report on Form 10-K for the fiscal year ended
December 31, 1997 filed with the Commission on March 17,
1998 (File No. 000-21249) and incorporated herein by
reference.
10.18+ Research Collaboration and License Agreement between the
Company and Amersham Pharmacia Biotech AB dated August 13,
1998. Filed as Exhibit 10.1 to the Company's Registration
Statement on Form S-3 (File No. 333-62203) and incorporated
herein by reference.
10.19+ Commercialization Agreement between the Company and Amersham
Pharmacia Biotech AB dated August 13, 1998. Filed as Exhibit
10.2 to the Company's Registration Statement on Form S-3
(File No. 333-62203) and incorporated herein by reference.
10.20+ Amendment No. 1 to Research and License Agreement between
the Company and Roche Bioscience, a division of Syntex,
Inc., dated as of September 30, 1998. Filed as Exhibit 10.1
to the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.21 Lease by and between MetroNorth Corporate Center LLC and the
Company dated as of May 29, 1998. Filed as Exhibit 10.3 to
the Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.22+ Compound Supply and License Agreement between the Company
and R.W. Johnson Pharmaceutical Research Institute, a
Division of Ortho-McNeil Pharmaceutical, Inc., dated as of
December 15, 1998. Filed as Exhibit 10.36 to the Company's
Annual Report on Form 10-K for the fiscal year ended
December 31, 1999, filed with the Commissioner on March 29,
1999 (File No. 000-21429) and incorporated herein by
reference.
48
50
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.23+ Employment agreement between Dr. Stephen A. Hill and the
Company dated as of December 8, 1998, as amended. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1999 (File No. 000-21429)
and incorporated herein by reference.
10.24 Term loan agreement between Fleet National Bank and the
Company, dated as of March 18, 1999. Filed as Exhibit 10.2
to the Company's Quarterly Report on Form 10-Q for the
Quarter ended March 31, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.25* Technology Acquisition Agreement between Pfizer Inc. and the
Company, dated as of July 19, 1999. Filed as Exhibit 10.1 to
the Company's Quarterly Report on Form 10-Q for the quarter
Ended September 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.26+ Sublease between Pfizer Inc. and the Company, dated July 16,
1999. Filed as Exhibit 10.2 to the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 1999
(File No. 000-21429) and incorporated herein by reference.
10.27+ Research Cooperation Agreement between Bayer AG and the
Company, dated October 1, 1999. Filed as Exhibit 10.3 to the
Company's Quarterly Report on Form 10-Q for the quarter
Ended September 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.28* Employment Agreement with Philippe Bey, dated July 21, 1999.
Filed as Exhibit 10.4 to the Company's Quarterly Report on
Form 10-Q for the quarter ended September 30, 1999 (File No.
000-21429) and incorporated herein by reference.
10.29+ Amended and Restated Array Delivery and Testing Agreement
between the Company and Monsanto Company dated as of January
11, 2000. Filed as Exhibit 10.1 to the Company's Current
Report on Form 8-K filed with the Commission on March 15,
2000 (File No. 000-21429) and incorporated herein by
reference.
10.30+ Array Delivery and Testing Agreement between the Company and
G.D. Searle & Co. dated June 20, 2000. Filed as Exhibit 10.1
to the Company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2000 (File No. 000-21429) and
incorporated herein by reference.
10.31+ Termination Agreement between the Company and Pharmacia
Corporation dated June 30, 2000. Filed as Exhibit 10.2 to
the Company's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2000 (File No. 000-21429) and incorporated
herein by reference.
10.32+ Technology Transfer and License Agreement between the
Company and Amersham Pharmacia Biotech A.B. dated July 10,
2000. Filed as Exhibit 10.3 to the Company's Quarterly
Report on Form 10-Q for the Quarter ended June 30, 2000
(File No. 000-21429) and incorporated herein by reference.
10.33* Employment agreement between the Company and Harold E.
Selick Dated as of January 29, 2001. Filed herewith.
10.34 Lease between Camitro Corporation and WVP Income Plus 3
dated February 4, 1999, as amended. Filed herewith.
10.35+ Compound Discovery Collaboration Agreement between the
Company and Genome Therapeutics Corporation dated October
17, 2000. Filed as Exhibit 10.1 to the Company's
Registration Statement on Form S-3 filed With the Commission
on October 20, 2000 (File No. 333-48358) and incorporated
herein by reference.
10.36+ Collaboration and License Agreement between the Company and
SmithKline Beecham Corporation dated November 27, 2000.
Filed herewith.
49
51
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.37+ Compound Discovery Collaboration Agreement between the
Company and ACADIA Pharmaceuticals, Inc. dated December 18,
2000. Filed herewith.
10.38+ Amendment No. 1 to the Compound Supply and License Agreement
between the Company and R.W. Johnson Pharmaceutical Research
Institute, a division of Ortho-McNeil Pharmaceutical, Inc.
dated as of August 14, 2000. Filed as Exhibit 99.1 to the
Company's Current Report on Form 8-K (File No. 000-21429)
filed with the Commission on October 17, 2000 and
incorporated herein by reference.
11.1 Statement re computation of per share net income (loss).
Filed herewith.
21.1 Subsidiaries of the Company. Filed herewith.
23.1 Consent of PricewaterhouseCoopers LLP. Filed herewith.
99.1 Important Factors Regarding Forward-Looking Statements.
Filed herewith.
- ---------------
* Indicates a management contract or compensatory plan.
+ Certain confidential material contained in the document has been omitted and
filed separately, with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended or Rule 24b-2 of the Securities
and Exchange Act of 1934, as amended.
50
52
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Woburn,
Commonwealth of Massachusetts, on March 22, 2001.
ARQULE, INC.
By: /s/ STEPHEN A. HILL
------------------------------------
Stephen A. Hill
President and Chief Executive
Officer
SIGNATURE TITLE DATE
--------- ----- ----
/s/ STEPHEN A. HILL President, Chief Executive March 22, 2001
- --------------------------------------------------- Officer and Director (Principal
Stephen A. Hill Executive Officer)
/s/ DAVID C. HASTINGS Vice President, Chief Financial March 22, 2001
- --------------------------------------------------- Officer and Treasurer
David C. Hastings (Principal Financial Officer
and Principal Accounting
Officer)
/s/ LAURA AVAKIAN Director March 22, 2001
- ---------------------------------------------------
Laura Avakian
/s/ WERNER CAUTREELS Director March 22, 2001
- ---------------------------------------------------
Werner Cautreels
/s/ ARIEL ELIA Director March 22, 2001
- ---------------------------------------------------
Ariel Elia
/s/ L. PATRICK GAGE Director March 22, 2001
- ---------------------------------------------------
L. Patrick Gage
/s/ TUAN HA-NGOC Director March 22, 2001
- ---------------------------------------------------
Tuan Ha-Ngoc
/s/ MICHAEL ROSENBLATT Director March 22, 2001
- ---------------------------------------------------
Michael Rosenblatt
51
53
EXHIBIT INDEX
EXHIBIT
NO. DESCRIPTION
- ------- -----------
2.1 Agreement and Plan of Merger among the Company, Camitro
Acquisition Corporation, Camitro Corporation, and certain
stockholders of Camitro Corporation dated as of January 16,
2001. Previously filed as Exhibit 2.1 to the Company's
Current Report on Form 8-K (File No. 000-21429). Filed with
the Commission on February 1, 2001 and incorporated herein
by reference.
3.1 Amended and Restated Certificate of Incorporation of the
Company. Filed as Exhibit 3.1 to the Company's Registration
Statement on Form S-1 (File No. 333-22945) and incorporated
herein by reference.
3.2 Amended and Restated By-laws of the Company. Filed as
Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
4.1 Specimen Common Stock Certificate. Filed as Exhibit 4.1 to
the Company's Registration Statement on Form S-1 (File No.
333-11105) and incorporated herein by reference.
10.1* Amended and Restated 1994 Equity Incentive Plan, as ended
through April 8, 1998. Filed as Exhibit 10.1 to the
Company's Quarterly Report on Form 10-Q for the quarter
amended June 30, 1998 (File No. 000-21429) and incorporated
herein by reference.
10.2* Amended and Restated 1996 Employee Stock Purchase Plan.
Filed as Exhibit 10.1 to the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 1999 (File No.
000-21429) and incorporated herein by reference.
10.3* Amended and Restated 1996 Director Stock Option Plan. Filed
as Exhibit 10.3 to the Company's Annual Report on Form 10-K
For the fiscal year ended December 31, 1997 filed with the
Commission on March 17, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.4 Form of Indemnification Agreement between the Company and
its directors. Such agreements are materially different only
as to the signing directors and the dates of execution.
Filed as Exhibit 10.4 to the Company's Registration
Statement on Form S-1 (File No. 333-11105) and incorporated
herein by reference.
10.5 Lease Agreement, dated July 27, 1995, between the Company
and Cummings Properties Management, Inc. as amended. Filed
as Exhibit 10.7 to the Company's Registration Statement on
Form S-1 (File No. 333-11105) and incorporated herein by
reference.
10.6+ Research, Development and License Agreement between the
Company and Solvay Duphar B.V. dated November 2, 1995. Filed
as Exhibit 10.14 to the Company's Registration Statement on
Form S-1 (File No. 333-11105) and incorporated herein by
reference.
10.7+ Research & Development and License Agreement between the
Company and Abbott Laboratories dated June 15, 1995, as
amended. Filed as Exhibit 10.15 to the Company's
Registration Statement on Form S-1 (File No. 333-11105) and
incorporated herein by reference.
10.8* Adoption Agreement for Fidelity Management and Research
Company (the Company's 401(k) plan). Filed as Exhibit 10.18
to the Company's Registration Statement on Form S-1 (File
No. 333-11105) and incorporated herein by reference.
10.9+ Research and License Agreement between the Company and Roche
Bioscience dated September 13, 1996. Filed as Exhibit 10.19
to the Company's Registration Statement on Form S-1 (File
No. 333-11105) and incorporated herein by reference.
54
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.10+ Array Delivery and Testing Agreement between the Company and
Monsanto Company dated as of December 23, 1996. Filed as
Exhibit 10.20 to the Company's Registration Statement on
Form S-1 (File No. 333-22945) and incorporated herein by
reference.
10.11+ Amendment No. 2 to Research & Development License Agreement
between the Company and Abbott Laboratories dated as of
December 24, 1996. Filed as Exhibit 10.21 to the Company's
incorporated herein by reference.
10.12 Lease Agreement, dated December 20, 1996 between the Company
and Cummings Property Management, Inc. Filed as Exhibit
10.22 to the Company's Registration Statement on Form S-1
(File No. 333-22945) and incorporated herein by reference.
10.13+ Research and License Agreement between the Company and
American Home Products Corporation acting through its
Wyeth-Ayerst Research Division dated July 3, 1997. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 1997 (File No. 000-21249) and
incorporated herein by reference.
10.14+ Second Amendment to Option Agreement and Research and
Development Agreement between the Company and Amersham
Pharmacia Biotech AB dated September 23, 1996. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended September 30, 1997 (File No.
000-21429) and incorporated herein by reference.
10.15+ Third Amendment to Option Agreement and Research and
Development Agreement between the Company and Amersham
Pharmacia Biotech AB dated June 24, 1997. Filed as Exhibit
10.2 to the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 1997 (File No. 000-21429) and
incorporated herein by reference.
10.16+ Research and Development Agreement between the Company and
Sankyo Co., Ltd. dated November 1, 1997. Filed as Exhibit
10.29 to the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 1997, filed with the
Commission on March 17, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.17+ Amendment No. 3 to Research & Development and License
Agreement between the Company and Abbott Laboratories dated
December 23, 1997. Filed as Exhibit 10.30 to the Company's
Annual Report on Form 10-K for the fiscal year ended
December 31, 1997 filed with the Commission on March 17,
1998 (File No. 000-21249) and incorporated herein by
reference.
10.18+ Research Collaboration and License Agreement between the
Company and Amersham Pharmacia Biotech AB dated August 13,
1998. Filed as Exhibit 10.1 to the Company's Registration
Statement on Form S-3 (File No. 333-62203) and incorporated
herein by reference.
10.19+ Commercialization Agreement between the Company and Amersham
Pharmacia Biotech AB dated August 13, 1998. Filed as Exhibit
10.2 to the Company's Registration Statement on Form S-3
(File No. 333-62203) and incorporated herein by reference.
10.20+ Amendment No. 1 to Research and License Agreement between
the Company and Roche Bioscience, a division of Syntex,
Inc., dated as of September 30, 1998. Filed as Exhibit 10.1
to the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.21 Lease by and between MetroNorth Corporate Center LLC and the
Company dated as of May 29, 1998. Filed as Exhibit 10.3 to
the Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 1998 (File No. 000-21429) and
incorporated herein by reference.
10.22+ Compound Supply and License Agreement between the Company
and R.W. Johnson Pharmaceutical Research Institute, a
Division of Ortho-McNeil Pharmaceutical, Inc., dated as of
December 15, 1998. Filed as Exhibit 10.36 to the Company's
Annual Report on Form 10-K for the fiscal year ended
December 31, 1999, filed with the Commissioner on March 29,
1999 (File No. 000-21429) and incorporated herein by
reference.
55
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.23+ Employment agreement between Dr. Stephen A. Hill and the
Company dated as of December 8, 1998, as amended. Filed as
Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 1999 (File No. 000-21429)
and incorporated herein by reference.
10.24 Term loan agreement between Fleet National Bank and the
Company, dated as of March 18, 1999. Filed as Exhibit 10.2
to the Company's Quarterly Report on Form 10-Q for the
Quarter ended March 31, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.25* Technology Acquisition Agreement between Pfizer Inc. and the
Company, dated as of July 19, 1999. Filed as Exhibit 10.1 to
the Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.26+ Sublease between Pfizer Inc. and the Company, dated July 16,
1999. Filed as Exhibit 10.2 to the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 1999
(File No. 000-21429) and incorporated herein by reference.
10.27+ Research Cooperation Agreement between Bayer AG and the
Company, dated October 1, 1999. Filed as Exhibit 10.3 to the
Company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 1999 (File No. 000-21429) and
incorporated herein by reference.
10.28* Employment Agreement with Philippe Bey, dated July 21, 1999.
Filed as Exhibit 10.4 to the Company's Quarterly Report on
Form 10-Q for the quarter ended September 30, 1999 (File No.
000-21429) and incorporated herein by reference.
10.29+ Amended and Restated Array Delivery and Testing Agreement
between the Company and Monsanto Company dated as of January
11, 2000. Filed as Exhibit 10.1 to the Company's Current
Report on Form 8-K filed with the Commission on March 15,
2000 (File No. 000-21429) and incorporated herein by
reference.
10.30+ Array Delivery and Testing Agreement between the Company and
G.D. Searle & Co. dated June 20, 2000. Filed as Exhibit 10.1
to the Company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2000 (File No. 000-21429) and
incorporated herein by reference.
10.31+ Termination Agreement between the Company and Pharmacia
Corporation dated June 30, 2000. Filed as Exhibit 10.2 to
the Company's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2000 (File No. 000-21429) and incorporated
herein by reference.
10.32+ Technology Transfer and License Agreement between the
Company and Amersham Pharmacia Biotech A.B. dated July 10,
2000. Filed as Exhibit 10.3 to the Company's Quarterly
Report on Form 10-Q for the Quarter ended June 30, 2000
(File No. 000-21429) and incorporated herein by reference.
10.33* Employment agreement between the Company and Harold E.
Selick Dated as of January 29, 2001. Filed herewith.
10.34 Lease between Camitro Corporation and WVP Income Plus 3
dated February 4, 1999, as amended. Filed herewith.
10.35+ Compound Discovery Collaboration Agreement between the
Company and Genome Therapeutics Corporation dated October
17, 2000. Filed as Exhibit 10.1 to the Company's
Registration Statement on Form S-3 filed With the Commission
on October 20, 2000 (File No. 333-48358) and incorporated
herein by reference.
10.36+ Collaboration and License Agreement between the Company and
SmithKline Beecham Corporation dated November 27, 2000.
Filed herewith.
56
EXHIBIT
NO. DESCRIPTION
- ------- -----------
10.37+ Compound Discovery Collaboration Agreement between the
Company and ACADIA Pharmaceuticals, Inc. dated December 18,
2000. Filed herewith.
10.38+ Amendment No. 1 to the Compound Supply and License Agreement
between the Company and R.W. Johnson Pharmaceutical Research
Institute, a division of Ortho-McNeil Pharmaceutical, Inc.
dated as of August 14, 2000. Filed as Exhibit 99.1 to the
Company's Current Report on Form 8-K (File No. 000-21429)
filed with the Commission on October 17, 2000 and
incorporated herein by reference.
11.1 Statement re computation of per share net income (loss).
Filed herewith.
21.1 Subsidiaries of the Company. Filed herewith.
23.1 Consent of PricewaterhouseCoopers LLP. Filed herewith.
99.1 Important Factors Regarding Forward-Looking Statements.
Filed herewith.
- ---------------
* Indicates a management contract or compensatory plan.
+ Certain confidential material contained in the document has been omitted and
filed separately, with the Securities and Exchange Commission pursuant to Rule
406 of the Securities Act of 1933, as amended or Rule 24b-2 of the Securities
and Exchange Act of 1934, as amended.